Trial Outcomes & Findings for Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A (NCT NCT00540592)
NCT ID: NCT00540592
Last Updated: 2018-06-08
Results Overview
Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
2007 participants
Primary outcome timeframe
At Day 21
Results posted on
2018-06-08
Participant Flow
Participant milestones
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
204
|
202
|
202
|
202
|
199
|
198
|
198
|
199
|
200
|
203
|
|
Overall Study
Completed at Day 180
|
200
|
201
|
197
|
197
|
195
|
198
|
196
|
193
|
198
|
189
|
|
Overall Study
COMPLETED
|
202
|
201
|
201
|
201
|
198
|
198
|
198
|
198
|
199
|
201
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
2
|
Reasons for withdrawal
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
|
Overall Study
Lost to Follow-up
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
Baseline characteristics by cohort
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
Total
n=2007 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
72.7 Years
STANDARD_DEVIATION 5.75 • n=5 Participants
|
72.6 Years
STANDARD_DEVIATION 5.16 • n=7 Participants
|
72.4 Years
STANDARD_DEVIATION 5.62 • n=5 Participants
|
72.9 Years
STANDARD_DEVIATION 6.09 • n=4 Participants
|
72.6 Years
STANDARD_DEVIATION 5.66 • n=21 Participants
|
72.7 Years
STANDARD_DEVIATION 5.56 • n=8 Participants
|
72.6 Years
STANDARD_DEVIATION 5.67 • n=8 Participants
|
73.0 Years
STANDARD_DEVIATION 6.03 • n=24 Participants
|
72.7 Years
STANDARD_DEVIATION 5.43 • n=42 Participants
|
27.4 Years
STANDARD_DEVIATION 6.25 • n=42 Participants
|
68.11 Years
STANDARD_DEVIATION 14.81 • n=42 Participants
|
|
Sex: Female, Male
Female
|
95 Participants
n=5 Participants
|
109 Participants
n=7 Participants
|
105 Participants
n=5 Participants
|
100 Participants
n=4 Participants
|
89 Participants
n=21 Participants
|
102 Participants
n=8 Participants
|
96 Participants
n=8 Participants
|
95 Participants
n=24 Participants
|
90 Participants
n=42 Participants
|
103 Participants
n=42 Participants
|
984 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
109 Participants
n=5 Participants
|
93 Participants
n=7 Participants
|
97 Participants
n=5 Participants
|
102 Participants
n=4 Participants
|
110 Participants
n=21 Participants
|
96 Participants
n=8 Participants
|
102 Participants
n=8 Participants
|
104 Participants
n=24 Participants
|
110 Participants
n=42 Participants
|
100 Participants
n=42 Participants
|
1023 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: At Day 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=194 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=193 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=188 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Haemagglutination Inhibition (HI) Antibody Titers
A/Solomon Islands strain
|
82.3 titer
Interval 69.7 to 97.1
|
102.2 titer
Interval 87.0 to 119.9
|
98.2 titer
Interval 84.3 to 114.3
|
91.7 titer
Interval 76.9 to 109.3
|
113.2 titer
Interval 96.0 to 133.6
|
114.4 titer
Interval 97.1 to 134.8
|
78.5 titer
Interval 65.9 to 93.5
|
111.8 titer
Interval 93.3 to 134.0
|
59.6 titer
Interval 49.6 to 71.7
|
—
|
|
Haemagglutination Inhibition (HI) Antibody Titers
A/Wisconsin strain
|
276.2 titer
Interval 238.8 to 319.6
|
350.2 titer
Interval 298.0 to 411.4
|
351.3 titer
Interval 304.8 to 404.8
|
309.2 titer
Interval 264.9 to 361.0
|
331.1 titer
Interval 289.6 to 378.6
|
438.1 titer
Interval 379.7 to 505.4
|
263.3 titer
Interval 225.3 to 307.7
|
347.5 titer
Interval 296.4 to 407.3
|
186.7 titer
Interval 158.0 to 220.7
|
—
|
|
Haemagglutination Inhibition (HI) Antibody Titers
B/Malaysia strain
|
147.1 titer
Interval 129.1 to 167.6
|
163.1 titer
Interval 142.5 to 186.6
|
172.1 titer
Interval 149.9 to 197.6
|
152.4 titer
Interval 134.4 to 172.7
|
181.4 titer
Interval 158.9 to 207.1
|
202.0 titer
Interval 179.7 to 227.1
|
155.7 titer
Interval 134.8 to 179.8
|
174.6 titer
Interval 152.0 to 200.7
|
153.0 titer
Interval 135.2 to 173.1
|
—
|
SECONDARY outcome
Timeframe: At Day 0 and 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=194 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=193 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=188 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=197 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
HI Antibody Titers at Day 0 and Day 21
A/Wisconsin strain at Day 21
|
276.2 titer
Interval 238.8 to 319.6
|
350.2 titer
Interval 298.0 to 411.4
|
351.3 titer
Interval 304.8 to 404.8
|
309.2 titer
Interval 264.9 to 361.0
|
331.1 titer
Interval 289.6 to 378.6
|
438.1 titer
Interval 379.7 to 505.4
|
263.3 titer
Interval 225.3 to 307.7
|
347.5 titer
Interval 296.4 to 407.3
|
186.7 titer
Interval 158.0 to 220.7
|
380.2 titer
Interval 331.6 to 435.9
|
|
HI Antibody Titers at Day 0 and Day 21
B/Malaysia strain at Day 0
|
58.6 titer
Interval 49.8 to 68.9
|
53.7 titer
Interval 45.7 to 63.2
|
57.0 titer
Interval 48.2 to 67.5
|
62.6 titer
Interval 53.3 to 73.4
|
77.8 titer
Interval 66.0 to 91.7
|
62.9 titer
Interval 53.9 to 73.4
|
58.2 titer
Interval 49.0 to 69.1
|
62.6 titer
Interval 53.0 to 74.0
|
66.5 titer
Interval 56.5 to 78.3
|
23.4 titer
Interval 19.1 to 28.7
|
|
HI Antibody Titers at Day 0 and Day 21
B/Malaysia strain at Day 21
|
147.1 titer
Interval 129.1 to 167.6
|
163.1 titer
Interval 142.5 to 186.6
|
172.1 titer
Interval 149.9 to 197.6
|
152.4 titer
Interval 134.4 to 172.7
|
181.4 titer
Interval 158.9 to 207.1
|
202.0 titer
Interval 179.7 to 227.1
|
155.7 titer
Interval 134.8 to 179.8
|
174.6 titer
Interval 152.0 to 200.7
|
153.0 titer
Interval 135.2 to 173.1
|
281.9 titer
Interval 241.7 to 328.7
|
|
HI Antibody Titers at Day 0 and Day 21
A/Solomon Islands strain at Day 0
|
10.6 titer
Interval 9.3 to 12.2
|
10.8 titer
Interval 9.4 to 12.4
|
10.1 titer
Interval 8.8 to 11.5
|
10.6 titer
Interval 9.3 to 12.1
|
12.0 titer
Interval 10.3 to 14.0
|
9.9 titer
Interval 8.6 to 11.3
|
10.2 titer
Interval 8.9 to 11.7
|
10.3 titer
Interval 9.0 to 11.9
|
10.7 titer
Interval 9.2 to 12.4
|
21.3 titer
Interval 17.1 to 26.5
|
|
HI Antibody Titers at Day 0 and Day 21
A/Solomon Islands strain at Day 21
|
82.3 titer
Interval 69.7 to 97.1
|
102.2 titer
Interval 87.0 to 119.9
|
98.2 titer
Interval 84.3 to 114.3
|
91.7 titer
Interval 76.9 to 109.3
|
113.2 titer
Interval 96.0 to 133.6
|
114.4 titer
Interval 97.1 to 134.8
|
78.5 titer
Interval 65.9 to 93.5
|
111.8 titer
Interval 93.3 to 134.0
|
59.6 titer
Interval 49.6 to 71.7
|
271.6 titer
Interval 224.6 to 328.4
|
|
HI Antibody Titers at Day 0 and Day 21
A/Wisconsin strain at Day 0
|
59.9 titer
Interval 49.5 to 72.4
|
51.2 titer
Interval 41.9 to 62.4
|
44.4 titer
Interval 36.5 to 54.0
|
65.7 titer
Interval 53.7 to 80.4
|
61.1 titer
Interval 50.6 to 73.8
|
55.8 titer
Interval 46.2 to 67.4
|
54.6 titer
Interval 44.5 to 67.0
|
57.8 titer
Interval 47.1 to 70.9
|
61.0 titer
Interval 49.8 to 74.7
|
47.8 titer
Interval 39.2 to 58.4
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=184 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=174 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=181 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=165 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
HI Antibody Titers at Day 180
A/Solomon Islands strain
|
30.6 titer
Interval 25.8 to 36.3
|
35.1 titer
Interval 29.7 to 41.5
|
36.3 titer
Interval 30.7 to 42.8
|
32.5 titer
Interval 27.6 to 38.2
|
40.4 titer
Interval 34.1 to 47.9
|
33.7 titer
Interval 28.6 to 39.7
|
29.9 titer
Interval 25.5 to 35.0
|
39.8 titer
Interval 33.6 to 47.2
|
23.7 titer
Interval 20.3 to 27.7
|
114.7 titer
Interval 91.8 to 143.5
|
|
HI Antibody Titers at Day 180
A/Wisconsin strain
|
131.5 titer
Interval 112.6 to 153.5
|
139.8 titer
Interval 118.1 to 165.5
|
133.4 titer
Interval 112.7 to 158.1
|
134.0 titer
Interval 113.1 to 158.7
|
144.7 titer
Interval 124.9 to 167.5
|
181.4 titer
Interval 156.5 to 210.3
|
118.2 titer
Interval 99.8 to 140.0
|
145.3 titer
Interval 121.9 to 173.2
|
92.5 titer
Interval 78.7 to 108.6
|
193.2 titer
Interval 163.5 to 228.3
|
|
HI Antibody Titers at Day 180
B/Malaysia strain
|
92.7 titer
Interval 81.2 to 106.0
|
94.3 titer
Interval 81.6 to 109.1
|
100.9 titer
Interval 87.7 to 116.1
|
87.4 titer
Interval 75.9 to 100.6
|
109.2 titer
Interval 94.9 to 125.6
|
111.4 titer
Interval 97.2 to 127.6
|
89.0 titer
Interval 76.1 to 104.0
|
97.7 titer
Interval 84.7 to 112.7
|
96.6 titer
Interval 83.8 to 111.3
|
132.4 titer
Interval 110.2 to 159.0
|
SECONDARY outcome
Timeframe: At Day 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=194 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=193 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=187 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=197 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 21
A/Solomon Islands strain
|
133 Subjects
|
138 Subjects
|
154 Subjects
|
130 Subjects
|
142 Subjects
|
151 Subjects
|
129 Subjects
|
146 Subjects
|
99 Subjects
|
135 Subjects
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 21
A/Wisconsin strain
|
108 Subjects
|
124 Subjects
|
141 Subjects
|
104 Subjects
|
124 Subjects
|
142 Subjects
|
110 Subjects
|
131 Subjects
|
69 Subjects
|
130 Subjects
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 21
B/Malaysia strain
|
47 Subjects
|
73 Subjects
|
65 Subjects
|
44 Subjects
|
45 Subjects
|
79 Subjects
|
50 Subjects
|
55 Subjects
|
47 Subjects
|
147 Subjects
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=184 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=174 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=180 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=165 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 180
A/Solomon Islands strain
|
64 Subjects
|
73 Subjects
|
74 Subjects
|
68 Subjects
|
60 Subjects
|
77 Subjects
|
60 Subjects
|
67 Subjects
|
42 Subjects
|
90 Subjects
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 180
A/Wisconsin strain
|
47 Subjects
|
59 Subjects
|
61 Subjects
|
46 Subjects
|
50 Subjects
|
74 Subjects
|
37 Subjects
|
49 Subjects
|
23 Subjects
|
74 Subjects
|
|
The Number of Subjects Seroconverted to HI Antibodies at Day 180
B/Malaysia strain
|
23 Subjects
|
23 Subjects
|
25 Subjects
|
19 Subjects
|
16 Subjects
|
32 Subjects
|
19 Subjects
|
20 Subjects
|
17 Subjects
|
90 Subjects
|
SECONDARY outcome
Timeframe: At Day 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=194 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=193 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=187 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=197 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
HI Antibody Seroconversion Factors at Day 21
A/Solomon Islands strain
|
7.7 fold increase
Interval 6.5 to 9.2
|
9.4 fold increase
Interval 7.8 to 11.3
|
9.8 fold increase
Interval 8.3 to 11.5
|
8.6 fold increase
Interval 7.2 to 10.4
|
9.4 fold increase
Interval 8.0 to 11.1
|
11.6 fold increase
Interval 9.7 to 13.9
|
7.7 fold increase
Interval 6.5 to 9.2
|
10.8 fold increase
Interval 9.0 to 13.0
|
5.6 fold increase
Interval 4.7 to 6.8
|
12.8 fold increase
Interval 10.0 to 16.3
|
|
HI Antibody Seroconversion Factors at Day 21
A/Wisconsin strain
|
4.6 fold increase
Interval 3.9 to 5.4
|
6.8 fold increase
Interval 5.6 to 8.1
|
7.9 fold increase
Interval 6.6 to 9.5
|
4.7 fold increase
Interval 4.0 to 5.5
|
5.4 fold increase
Interval 4.6 to 6.3
|
7.8 fold increase
Interval 6.5 to 9.5
|
4.8 fold increase
Interval 4.1 to 5.7
|
6.0 fold increase
Interval 5.1 to 7.1
|
3.1 fold increase
Interval 2.6 to 3.6
|
7.9 fold increase
Interval 6.4 to 9.8
|
|
HI Antibody Seroconversion Factors at Day 21
B/Malaysia strain
|
2.5 fold increase
Interval 2.2 to 2.8
|
3.0 fold increase
Interval 2.6 to 3.5
|
3.0 fold increase
Interval 2.6 to 3.5
|
2.4 fold increase
Interval 2.2 to 2.8
|
2.3 fold increase
Interval 2.1 to 2.6
|
3.2 fold increase
Interval 2.8 to 3.7
|
2.7 fold increase
Interval 2.3 to 3.1
|
2.8 fold increase
Interval 2.4 to 3.2
|
2.3 fold increase
Interval 2.0 to 2.6
|
12.0 fold increase
Interval 9.7 to 15.0
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=184 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=174 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=180 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=165 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
HI Antibody Seroconversion Factors at Day 180
A/Solomon Islands strain
|
2.9 fold increase
Interval 2.5 to 3.4
|
3.3 fold increase
Interval 2.8 to 3.9
|
3.5 fold increase
Interval 3.1 to 4.1
|
3.0 fold increase
Interval 2.6 to 3.5
|
3.3 fold increase
Interval 2.9 to 3.8
|
3.5 fold increase
Interval 2.9 to 4.1
|
2.9 fold increase
Interval 2.5 to 3.3
|
3.8 fold increase
Interval 3.2 to 4.4
|
2.2 fold increase
Interval 1.9 to 2.6
|
5.7 fold increase
Interval 4.5 to 7.2
|
|
HI Antibody Seroconversion Factors at Day 180
A/Wisconsin strain
|
2.2 fold increase
Interval 1.9 to 2.6
|
2.7 fold increase
Interval 2.3 to 3.1
|
2.9 fold increase
Interval 2.5 to 3.3
|
2.0 fold increase
Interval 1.8 to 2.3
|
2.4 fold increase
Interval 2.1 to 2.7
|
3.1 fold increase
Interval 2.7 to 3.6
|
2.1 fold increase
Interval 1.8 to 2.4
|
2.5 fold increase
Interval 2.2 to 2.9
|
1.6 fold increase
Interval 1.4 to 1.8
|
4.0 fold increase
Interval 3.2 to 5.0
|
|
HI Antibody Seroconversion Factors at Day 180
B/Malaysia strain
|
1.7 fold increase
Interval 1.5 to 1.9
|
1.7 fold increase
Interval 1.5 to 1.9
|
1.7 fold increase
Interval 1.5 to 1.9
|
1.4 fold increase
Interval 1.3 to 1.6
|
1.4 fold increase
Interval 1.3 to 1.6
|
1.8 fold increase
Interval 1.6 to 2.0
|
1.5 fold increase
Interval 1.4 to 1.7
|
1.6 fold increase
Interval 1.4 to 1.8
|
1.5 fold increase
Interval 1.3 to 1.7
|
5.6 fold increase
Interval 4.5 to 7.0
|
SECONDARY outcome
Timeframe: At Day 0 and 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=191 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=194 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=193 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=192 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=189 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=188 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=197 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
A/Solomon Islands strain at Day 0
|
27 Subjects
|
31 Subjects
|
25 Subjects
|
33 Subjects
|
44 Subjects
|
23 Subjects
|
22 Subjects
|
26 Subjects
|
31 Subjects
|
69 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
A/Solomon Islands strain at Day 21
|
160 Subjects
|
168 Subjects
|
171 Subjects
|
158 Subjects
|
169 Subjects
|
172 Subjects
|
153 Subjects
|
163 Subjects
|
132 Subjects
|
182 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
A/Wisconsin strain at Day 0
|
133 Subjects
|
124 Subjects
|
113 Subjects
|
139 Subjects
|
131 Subjects
|
139 Subjects
|
130 Subjects
|
134 Subjects
|
132 Subjects
|
122 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
A/Wisconsin strain at Day 21
|
188 Subjects
|
189 Subjects
|
188 Subjects
|
190 Subjects
|
192 Subjects
|
191 Subjects
|
187 Subjects
|
185 Subjects
|
179 Subjects
|
197 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
B/Malaysia strain at Day 0
|
138 Subjects
|
140 Subjects
|
138 Subjects
|
148 Subjects
|
156 Subjects
|
149 Subjects
|
139 Subjects
|
145 Subjects
|
144 Subjects
|
77 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
B/Malaysia strain at Day 21
|
183 Subjects
|
183 Subjects
|
184 Subjects
|
187 Subjects
|
186 Subjects
|
192 Subjects
|
182 Subjects
|
184 Subjects
|
183 Subjects
|
195 Subjects
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=186 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=184 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=180 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=187 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=174 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=181 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=165 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 180
B/Malaysia strain
|
167 Subjects
|
166 Subjects
|
168 Subjects
|
168 Subjects
|
166 Subjects
|
176 Subjects
|
158 Subjects
|
162 Subjects
|
162 Subjects
|
144 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 180
A/Solomon Islands strain
|
94 Subjects
|
111 Subjects
|
105 Subjects
|
105 Subjects
|
103 Subjects
|
104 Subjects
|
100 Subjects
|
100 Subjects
|
77 Subjects
|
135 Subjects
|
|
The Number of Subjects Seroprotected to HI Antibodies at Day 180
A/Wisconsin strain
|
172 Subjects
|
170 Subjects
|
162 Subjects
|
164 Subjects
|
170 Subjects
|
179 Subjects
|
166 Subjects
|
160 Subjects
|
156 Subjects
|
158 Subjects
|
SECONDARY outcome
Timeframe: At Days 0 and 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.
The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=19 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=25 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=23 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=23 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-All doubles] at Day 0
|
407.18 cells per million CD4 T-cells
Standard Deviation 456.82
|
596.53 cells per million CD4 T-cells
Standard Deviation 400.24
|
500.81 cells per million CD4 T-cells
Standard Deviation 734.64
|
250.48 cells per million CD4 T-cells
Standard Deviation 375.23
|
490.56 cells per million CD4 T-cells
Standard Deviation 546.12
|
259.15 cells per million CD4 T-cells
Standard Deviation 278.35
|
403.06 cells per million CD4 T-cells
Standard Deviation 482.16
|
442.39 cells per million CD4 T-cells
Standard Deviation 315.27
|
301.23 cells per million CD4 T-cells
Standard Deviation 584.68
|
1098.75 cells per million CD4 T-cells
Standard Deviation 909.18
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-IFNγ] at Day 0
|
202.65 cells per million CD4 T-cells
Standard Deviation 195.65
|
190.19 cells per million CD4 T-cells
Standard Deviation 245.89
|
158.04 cells per million CD4 T-cells
Standard Deviation 192.23
|
235.01 cells per million CD4 T-cells
Standard Deviation 355.44
|
171.07 cells per million CD4 T-cells
Standard Deviation 194.84
|
137.02 cells per million CD4 T-cells
Standard Deviation 189.76
|
203.95 cells per million CD4 T-cells
Standard Deviation 254.48
|
184.52 cells per million CD4 T-cells
Standard Deviation 211.26
|
198.86 cells per million CD4 T-cells
Standard Deviation 422.78
|
380.34 cells per million CD4 T-cells
Standard Deviation 384.07
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-IFNγ] at Day 21
|
644.07 cells per million CD4 T-cells
Standard Deviation 707.63
|
891.98 cells per million CD4 T-cells
Standard Deviation 719.87
|
809.46 cells per million CD4 T-cells
Standard Deviation 590.21
|
606.43 cells per million CD4 T-cells
Standard Deviation 745.80
|
651.21 cells per million CD4 T-cells
Standard Deviation 651.51
|
1293.10 cells per million CD4 T-cells
Standard Deviation 2390.91
|
718.87 cells per million CD4 T-cells
Standard Deviation 619.16
|
691.57 cells per million CD4 T-cells
Standard Deviation 2944.57
|
548.91 cells per million CD4 T-cells
Standard Deviation 732.46
|
976.96 cells per million CD4 T-cells
Standard Deviation 643.43
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-TNFα] at Day 0
|
91.32 cells per million CD4 T-cells
Standard Deviation 201.60
|
155.22 cells per million CD4 T-cells
Standard Deviation 184.44
|
130.19 cells per million CD4 T-cells
Standard Deviation 152.33
|
124.70 cells per million CD4 T-cells
Standard Deviation 306.20
|
143.44 cells per million CD4 T-cells
Standard Deviation 199.20
|
112.41 cells per million CD4 T-cells
Standard Deviation 169.39
|
100.38 cells per million CD4 T-cells
Standard Deviation 185.42
|
111.07 cells per million CD4 T-cells
Standard Deviation 179.39
|
104.10 cells per million CD4 T-cells
Standard Deviation 311.25
|
234.98 cells per million CD4 T-cells
Standard Deviation 234.23
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-All doubles] at Day 0
|
177.48 cells per million CD4 T-cells
Standard Deviation 278.18
|
283.18 cells per million CD4 T-cells
Standard Deviation 319.74
|
204.49 cells per million CD4 T-cells
Standard Deviation 236.05
|
200.21 cells per million CD4 T-cells
Standard Deviation 480.41
|
193.35 cells per million CD4 T-cells
Standard Deviation 324.34
|
177.44 cells per million CD4 T-cells
Standard Deviation 297.52
|
199.80 cells per million CD4 T-cells
Standard Deviation 310.58
|
222.58 cells per million CD4 T-cells
Standard Deviation 282.91
|
156.21 cells per million CD4 T-cells
Standard Deviation 518.89
|
538.72 cells per million CD4 T-cells
Standard Deviation 442.78
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-All doubles] at Day 21
|
441.16 cells per million CD4 T-cells
Standard Deviation 517.73
|
856.00 cells per million CD4 T-cells
Standard Deviation 685.35
|
704.14 cells per million CD4 T-cells
Standard Deviation 778.07
|
494.63 cells per million CD4 T-cells
Standard Deviation 883.53
|
483.24 cells per million CD4 T-cells
Standard Deviation 481.37
|
808.90 cells per million CD4 T-cells
Standard Deviation 858.38
|
655.32 cells per million CD4 T-cells
Standard Deviation 616.75
|
797.68 cells per million CD4 T-cells
Standard Deviation 5271.86
|
536.24 cells per million CD4 T-cells
Standard Deviation 578.48
|
1027.23 cells per million CD4 T-cells
Standard Deviation 838.01
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-All doubles] at Day 0
|
583.77 cells per million CD4 T-cells
Standard Deviation 563.98
|
488.70 cells per million CD4 T-cells
Standard Deviation 540.66
|
584.25 cells per million CD4 T-cells
Standard Deviation 626.26
|
309.67 cells per million CD4 T-cells
Standard Deviation 517.11
|
538.87 cells per million CD4 T-cells
Standard Deviation 691.59
|
702.79 cells per million CD4 T-cells
Standard Deviation 3741.48
|
457.98 cells per million CD4 T-cells
Standard Deviation 321.69
|
594.26 cells per million CD4 T-cells
Standard Deviation 598.83
|
427.71 cells per million CD4 T-cells
Standard Deviation 745.78
|
821.78 cells per million CD4 T-cells
Standard Deviation 646.48
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-All doubles] at Day 21
|
1016.63 cells per million CD4 T-cells
Standard Deviation 990.97
|
1491.86 cells per million CD4 T-cells
Standard Deviation 899.50
|
1140.56 cells per million CD4 T-cells
Standard Deviation 955.61
|
1015.18 cells per million CD4 T-cells
Standard Deviation 1044.87
|
1051.06 cells per million CD4 T-cells
Standard Deviation 1024.97
|
1998.33 cells per million CD4 T-cells
Standard Deviation 2730.32
|
1234.37 cells per million CD4 T-cells
Standard Deviation 830.47
|
1302.34 cells per million CD4 T-cells
Standard Deviation 3490.03
|
922.62 cells per million CD4 T-cells
Standard Deviation 1170.30
|
1455.68 cells per million CD4 T-cells
Standard Deviation 870.69
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-All doubles] at Day 21
|
1025.01 cells per million CD4 T-cells
Standard Deviation 736.55
|
1614.14 cells per million CD4 T-cells
Standard Deviation 953.74
|
1005.72 cells per million CD4 T-cells
Standard Deviation 1314.69
|
817.57 cells per million CD4 T-cells
Standard Deviation 675.70
|
1019.48 cells per million CD4 T-cells
Standard Deviation 698.91
|
1255.53 cells per million CD4 T-cells
Standard Deviation 941.27
|
1153.76 cells per million CD4 T-cells
Standard Deviation 699.26
|
1057.60 cells per million CD4 T-cells
Standard Deviation 4968.52
|
781.66 cells per million CD4 T-cells
Standard Deviation 880.46
|
1707.62 cells per million CD4 T-cells
Standard Deviation 1591.31
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-CD40L] at Day 0
|
187.19 cells per million CD4 T-cells
Standard Deviation 277.14
|
285.19 cells per million CD4 T-cells
Standard Deviation 319.80
|
193.56 cells per million CD4 T-cells
Standard Deviation 236.01
|
141.26 cells per million CD4 T-cells
Standard Deviation 500.24
|
192.02 cells per million CD4 T-cells
Standard Deviation 314.38
|
167.87 cells per million CD4 T-cells
Standard Deviation 296.47
|
153.91 cells per million CD4 T-cells
Standard Deviation 311.96
|
165.48 cells per million CD4 T-cells
Standard Deviation 281.57
|
150.60 cells per million CD4 T-cells
Standard Deviation 512.37
|
504.55 cells per million CD4 T-cells
Standard Deviation 441.35
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-CD40L] at Day 21
|
418.24 cells per million CD4 T-cells
Standard Deviation 523.39
|
657.41 cells per million CD4 T-cells
Standard Deviation 684.48
|
641.98 cells per million CD4 T-cells
Standard Deviation 752.95
|
471.56 cells per million CD4 T-cells
Standard Deviation 881.73
|
391.29 cells per million CD4 T-cells
Standard Deviation 474.16
|
510.16 cells per million CD4 T-cells
Standard Deviation 871.38
|
599.32 cells per million CD4 T-cells
Standard Deviation 592.08
|
697.39 cells per million CD4 T-cells
Standard Deviation 5282.26
|
406.14 cells per million CD4 T-cells
Standard Deviation 571.70
|
967.83 cells per million CD4 T-cells
Standard Deviation 848.55
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-CD40L] at Day 0
|
555.20 cells per million CD4 T-cells
Standard Deviation 555.43
|
477.12 cells per million CD4 T-cells
Standard Deviation 531.36
|
527.80 cells per million CD4 T-cells
Standard Deviation 613.23
|
284.63 cells per million CD4 T-cells
Standard Deviation 522.58
|
511.21 cells per million CD4 T-cells
Standard Deviation 679.89
|
587.17 cells per million CD4 T-cells
Standard Deviation 1872.24
|
418.98 cells per million CD4 T-cells
Standard Deviation 333.83
|
568.96 cells per million CD4 T-cells
Standard Deviation 559.46
|
322.37 cells per million CD4 T-cells
Standard Deviation 713.98
|
742.80 cells per million CD4 T-cells
Standard Deviation 659.21
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-CD40L] at Day 21
|
941.04 cells per million CD4 T-cells
Standard Deviation 994.45
|
1438.93 cells per million CD4 T-cells
Standard Deviation 881.80
|
1014.97 cells per million CD4 T-cells
Standard Deviation 933.09
|
940.53 cells per million CD4 T-cells
Standard Deviation 1065.84
|
977.44 cells per million CD4 T-cells
Standard Deviation 970.75
|
1763.75 cells per million CD4 T-cells
Standard Deviation 1858.49
|
1162.09 cells per million CD4 T-cells
Standard Deviation 715.63
|
1156.07 cells per million CD4 T-cells
Standard Deviation 3501.25
|
798.75 cells per million CD4 T-cells
Standard Deviation 1155.23
|
1383.25 cells per million CD4 T-cells
Standard Deviation 871.98
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-CD40L] at Day 0
|
387.03 cells per million CD4 T-cells
Standard Deviation 429.86
|
587.72 cells per million CD4 T-cells
Standard Deviation 396.47
|
446.80 cells per million CD4 T-cells
Standard Deviation 736.88
|
219.83 cells per million CD4 T-cells
Standard Deviation 386.13
|
479.21 cells per million CD4 T-cells
Standard Deviation 550.01
|
256.73 cells per million CD4 T-cells
Standard Deviation 280.28
|
383.93 cells per million CD4 T-cells
Standard Deviation 466.87
|
431.32 cells per million CD4 T-cells
Standard Deviation 319.06
|
342.65 cells per million CD4 T-cells
Standard Deviation 589.08
|
1076.46 cells per million CD4 T-cells
Standard Deviation 903.85
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-CD40L] at Day 21
|
926.13 cells per million CD4 T-cells
Standard Deviation 749.19
|
1570.30 cells per million CD4 T-cells
Standard Deviation 962.36
|
958.63 cells per million CD4 T-cells
Standard Deviation 1315.41
|
754.45 cells per million CD4 T-cells
Standard Deviation 694.91
|
975.92 cells per million CD4 T-cells
Standard Deviation 710.25
|
1160.31 cells per million CD4 T-cells
Standard Deviation 959.34
|
1039.13 cells per million CD4 T-cells
Standard Deviation 699.33
|
957.22 cells per million CD4 T-cells
Standard Deviation 5023.06
|
707.72 cells per million CD4 T-cells
Standard Deviation 874.64
|
1614.08 cells per million CD4 T-cells
Standard Deviation 1617.78
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-IFNγ] at Day 21
|
398.57 cells per million CD4 T-cells
Standard Deviation 370.41
|
636.42 cells per million CD4 T-cells
Standard Deviation 570.57
|
532.84 cells per million CD4 T-cells
Standard Deviation 488.63
|
426.15 cells per million CD4 T-cells
Standard Deviation 660.07
|
379.49 cells per million CD4 T-cells
Standard Deviation 361.80
|
543.09 cells per million CD4 T-cells
Standard Deviation 681.65
|
467.66 cells per million CD4 T-cells
Standard Deviation 450.93
|
576.14 cells per million CD4 T-cells
Standard Deviation 4664.15
|
442.66 cells per million CD4 T-cells
Standard Deviation 449.36
|
755.12 cells per million CD4 T-cells
Standard Deviation 645.89
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-IFNγ] at Day 0
|
361.99 cells per million CD4 T-cells
Standard Deviation 378.72
|
350.04 cells per million CD4 T-cells
Standard Deviation 325.28
|
332.39 cells per million CD4 T-cells
Standard Deviation 326.71
|
295.56 cells per million CD4 T-cells
Standard Deviation 424.20
|
243.93 cells per million CD4 T-cells
Standard Deviation 321.57
|
495.18 cells per million CD4 T-cells
Standard Deviation 3550.69
|
305.13 cells per million CD4 T-cells
Standard Deviation 248.40
|
310.45 cells per million CD4 T-cells
Standard Deviation 276.10
|
272.34 cells per million CD4 T-cells
Standard Deviation 453.35
|
589.57 cells per million CD4 T-cells
Standard Deviation 493.89
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-IFNγ] at Day 0
|
336.70 cells per million CD4 T-cells
Standard Deviation 352.20
|
403.08 cells per million CD4 T-cells
Standard Deviation 319.99
|
322.07 cells per million CD4 T-cells
Standard Deviation 631.98
|
302.23 cells per million CD4 T-cells
Standard Deviation 249.59
|
248.66 cells per million CD4 T-cells
Standard Deviation 236.24
|
237.57 cells per million CD4 T-cells
Standard Deviation 200.43
|
277.94 cells per million CD4 T-cells
Standard Deviation 372.05
|
210.23 cells per million CD4 T-cells
Standard Deviation 266.19
|
256.03 cells per million CD4 T-cells
Standard Deviation 440.55
|
874.82 cells per million CD4 T-cells
Standard Deviation 729.66
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-IFNγ] at Day 21
|
716.86 cells per million CD4 T-cells
Standard Deviation 601.16
|
1163.80 cells per million CD4 T-cells
Standard Deviation 865.47
|
855.95 cells per million CD4 T-cells
Standard Deviation 1073.89
|
509.84 cells per million CD4 T-cells
Standard Deviation 520.06
|
611.65 cells per million CD4 T-cells
Standard Deviation 527.80
|
852.80 cells per million CD4 T-cells
Standard Deviation 715.28
|
745.46 cells per million CD4 T-cells
Standard Deviation 575.21
|
709.84 cells per million CD4 T-cells
Standard Deviation 4385.83
|
523.15 cells per million CD4 T-cells
Standard Deviation 697.47
|
1306.18 cells per million CD4 T-cells
Standard Deviation 1346.37
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-IL2] at Day 0
|
181.54 cells per million CD4 T-cells
Standard Deviation 242.60
|
193.42 cells per million CD4 T-cells
Standard Deviation 297.22
|
188.29 cells per million CD4 T-cells
Standard Deviation 215.39
|
150.59 cells per million CD4 T-cells
Standard Deviation 407.63
|
152.22 cells per million CD4 T-cells
Standard Deviation 284.11
|
157.54 cells per million CD4 T-cells
Standard Deviation 255.06
|
161.81 cells per million CD4 T-cells
Standard Deviation 293.16
|
170.79 cells per million CD4 T-cells
Standard Deviation 253.02
|
122.12 cells per million CD4 T-cells
Standard Deviation 451.59
|
356.84 cells per million CD4 T-cells
Standard Deviation 313.43
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-IL2] at Day 21
|
299.14 cells per million CD4 T-cells
Standard Deviation 421.84
|
664.46 cells per million CD4 T-cells
Standard Deviation 582.79
|
559.98 cells per million CD4 T-cells
Standard Deviation 642.32
|
415.13 cells per million CD4 T-cells
Standard Deviation 691.39
|
409.73 cells per million CD4 T-cells
Standard Deviation 365.35
|
677.81 cells per million CD4 T-cells
Standard Deviation 689.59
|
529.19 cells per million CD4 T-cells
Standard Deviation 520.65
|
678.22 cells per million CD4 T-cells
Standard Deviation 4760.15
|
461.05 cells per million CD4 T-cells
Standard Deviation 498.00
|
813.73 cells per million CD4 T-cells
Standard Deviation 693.31
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-IL2] at Day 0
|
406.48 cells per million CD4 T-cells
Standard Deviation 508.99
|
382.61 cells per million CD4 T-cells
Standard Deviation 428.51
|
516.80 cells per million CD4 T-cells
Standard Deviation 421.85
|
251.35 cells per million CD4 T-cells
Standard Deviation 445.04
|
388.89 cells per million CD4 T-cells
Standard Deviation 560.47
|
532.86 cells per million CD4 T-cells
Standard Deviation 708.29
|
393.79 cells per million CD4 T-cells
Standard Deviation 295.93
|
470.64 cells per million CD4 T-cells
Standard Deviation 443.13
|
343.41 cells per million CD4 T-cells
Standard Deviation 607.93
|
589.89 cells per million CD4 T-cells
Standard Deviation 469.14
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-IL2] at Day 21
|
747.93 cells per million CD4 T-cells
Standard Deviation 778.49
|
1082.78 cells per million CD4 T-cells
Standard Deviation 712.53
|
1010.24 cells per million CD4 T-cells
Standard Deviation 772.39
|
762.07 cells per million CD4 T-cells
Standard Deviation 766.05
|
792.75 cells per million CD4 T-cells
Standard Deviation 828.41
|
1425.03 cells per million CD4 T-cells
Standard Deviation 1236.35
|
908.72 cells per million CD4 T-cells
Standard Deviation 680.48
|
1041.76 cells per million CD4 T-cells
Standard Deviation 2883.12
|
733.36 cells per million CD4 T-cells
Standard Deviation 900.95
|
1061.62 cells per million CD4 T-cells
Standard Deviation 635.42
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-IL2] at Day 0
|
277.98 cells per million CD4 T-cells
Standard Deviation 394.46
|
491.65 cells per million CD4 T-cells
Standard Deviation 369.85
|
434.78 cells per million CD4 T-cells
Standard Deviation 621.10
|
190.27 cells per million CD4 T-cells
Standard Deviation 322.46
|
411.11 cells per million CD4 T-cells
Standard Deviation 457.99
|
269.03 cells per million CD4 T-cells
Standard Deviation 243.51
|
360.78 cells per million CD4 T-cells
Standard Deviation 420.71
|
333.95 cells per million CD4 T-cells
Standard Deviation 309.81
|
221.19 cells per million CD4 T-cells
Standard Deviation 537.35
|
871.60 cells per million CD4 T-cells
Standard Deviation 724.64
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-IL2] at Day 21
|
791.31 cells per million CD4 T-cells
Standard Deviation 616.06
|
1295.22 cells per million CD4 T-cells
Standard Deviation 856.91
|
992.50 cells per million CD4 T-cells
Standard Deviation 1134.21
|
692.82 cells per million CD4 T-cells
Standard Deviation 570.55
|
876.95 cells per million CD4 T-cells
Standard Deviation 569.97
|
1038.01 cells per million CD4 T-cells
Standard Deviation 765.73
|
949.33 cells per million CD4 T-cells
Standard Deviation 588.11
|
872.00 cells per million CD4 T-cells
Standard Deviation 4655.93
|
695.83 cells per million CD4 T-cells
Standard Deviation 757.57
|
1348.21 cells per million CD4 T-cells
Standard Deviation 1359.92
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD4-TNFα] at Day 21
|
234.99 cells per million CD4 T-cells
Standard Deviation 298.31
|
440.26 cells per million CD4 T-cells
Standard Deviation 451.77
|
333.95 cells per million CD4 T-cells
Standard Deviation 487.76
|
279.64 cells per million CD4 T-cells
Standard Deviation 553.81
|
296.79 cells per million CD4 T-cells
Standard Deviation 289.33
|
336.45 cells per million CD4 T-cells
Standard Deviation 541.95
|
325.65 cells per million CD4 T-cells
Standard Deviation 410.44
|
449.86 cells per million CD4 T-cells
Standard Deviation 3979.03
|
273.66 cells per million CD4 T-cells
Standard Deviation 355.95
|
490.23 cells per million CD4 T-cells
Standard Deviation 532.90
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-TNFα] at Day 0
|
351.26 cells per million CD4 T-cells
Standard Deviation 450.82
|
458.02 cells per million CD4 T-cells
Standard Deviation 373.43
|
432.24 cells per million CD4 T-cells
Standard Deviation 487.63
|
342.30 cells per million CD4 T-cells
Standard Deviation 455.39
|
404.64 cells per million CD4 T-cells
Standard Deviation 410.30
|
600.83 cells per million CD4 T-cells
Standard Deviation 3581.08
|
303.13 cells per million CD4 T-cells
Standard Deviation 263.25
|
420.75 cells per million CD4 T-cells
Standard Deviation 422.38
|
327.09 cells per million CD4 T-cells
Standard Deviation 552.26
|
667.60 cells per million CD4 T-cells
Standard Deviation 450.65
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD4-TNFα] at Day 21
|
712.96 cells per million CD4 T-cells
Standard Deviation 700.26
|
944.29 cells per million CD4 T-cells
Standard Deviation 589.91
|
852.44 cells per million CD4 T-cells
Standard Deviation 637.30
|
623.21 cells per million CD4 T-cells
Standard Deviation 728.42
|
702.41 cells per million CD4 T-cells
Standard Deviation 635.67
|
1293.59 cells per million CD4 T-cells
Standard Deviation 2431.45
|
802.15 cells per million CD4 T-cells
Standard Deviation 591.12
|
884.71 cells per million CD4 T-cells
Standard Deviation 2654.95
|
575.97 cells per million CD4 T-cells
Standard Deviation 723.76
|
995.86 cells per million CD4 T-cells
Standard Deviation 630.33
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-TNFα] at Day 0
|
203.89 cells per million CD4 T-cells
Standard Deviation 281.14
|
239.73 cells per million CD4 T-cells
Standard Deviation 260.28
|
225.66 cells per million CD4 T-cells
Standard Deviation 501.91
|
118.04 cells per million CD4 T-cells
Standard Deviation 257.63
|
241.23 cells per million CD4 T-cells
Standard Deviation 332.43
|
117.51 cells per million CD4 T-cells
Standard Deviation 175.00
|
152.19 cells per million CD4 T-cells
Standard Deviation 297.33
|
193.88 cells per million CD4 T-cells
Standard Deviation 141.46
|
126.64 cells per million CD4 T-cells
Standard Deviation 402.92
|
605.04 cells per million CD4 T-cells
Standard Deviation 641.27
|
|
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD4-TNFα] at Day 21
|
509.26 cells per million CD4 T-cells
Standard Deviation 451.20
|
806.86 cells per million CD4 T-cells
Standard Deviation 561.77
|
601.64 cells per million CD4 T-cells
Standard Deviation 763.90
|
312.72 cells per million CD4 T-cells
Standard Deviation 391.89
|
518.35 cells per million CD4 T-cells
Standard Deviation 419.60
|
580.98 cells per million CD4 T-cells
Standard Deviation 579.68
|
547.64 cells per million CD4 T-cells
Standard Deviation 464.44
|
540.54 cells per million CD4 T-cells
Standard Deviation 3022.19
|
285.50 cells per million CD4 T-cells
Standard Deviation 526.85
|
805.41 cells per million CD4 T-cells
Standard Deviation 1133.76
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 180.
The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=21 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=18 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=20 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=17 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=21 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=21 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=19 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=16 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=16 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=19 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD4-All doubles]
|
802.04 cells per million CD4 T-cells
Standard Deviation 391.96
|
603.15 cells per million CD4 T-cells
Standard Deviation 559.07
|
720.91 cells per million CD4 T-cells
Standard Deviation 829.77
|
463.85 cells per million CD4 T-cells
Standard Deviation 832.67
|
728.09 cells per million CD4 T-cells
Standard Deviation 640.63
|
676.69 cells per million CD4 T-cells
Standard Deviation 785.39
|
670.60 cells per million CD4 T-cells
Standard Deviation 881.04
|
566.79 cells per million CD4 T-cells
Standard Deviation 522.16
|
638.11 cells per million CD4 T-cells
Standard Deviation 929.43
|
1366.02 cells per million CD4 T-cells
Standard Deviation 966.33
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD4-All doubles]
|
393.50 cells per million CD4 T-cells
Standard Deviation 359.42
|
348.12 cells per million CD4 T-cells
Standard Deviation 422.44
|
666.01 cells per million CD4 T-cells
Standard Deviation 663.86
|
394.45 cells per million CD4 T-cells
Standard Deviation 508.40
|
432.70 cells per million CD4 T-cells
Standard Deviation 374.70
|
421.08 cells per million CD4 T-cells
Standard Deviation 613.81
|
357.66 cells per million CD4 T-cells
Standard Deviation 470.53
|
224.47 cells per million CD4 T-cells
Standard Deviation 332.47
|
714.85 cells per million CD4 T-cells
Standard Deviation 658.37
|
1070.14 cells per million CD4 T-cells
Standard Deviation 874.71
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD4-All doubles]
|
679.05 cells per million CD4 T-cells
Standard Deviation 4150.67
|
807.74 cells per million CD4 T-cells
Standard Deviation 629.48
|
807.96 cells per million CD4 T-cells
Standard Deviation 901.44
|
416.48 cells per million CD4 T-cells
Standard Deviation 442.15
|
774.07 cells per million CD4 T-cells
Standard Deviation 452.40
|
423.03 cells per million CD4 T-cells
Standard Deviation 839.74
|
582.68 cells per million CD4 T-cells
Standard Deviation 429.62
|
588.22 cells per million CD4 T-cells
Standard Deviation 334.48
|
742.01 cells per million CD4 T-cells
Standard Deviation 481.80
|
1304.54 cells per million CD4 T-cells
Standard Deviation 1096.30
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD4-CD40L]
|
348.06 cells per million CD4 T-cells
Standard Deviation 342.53
|
319.80 cells per million CD4 T-cells
Standard Deviation 403.11
|
622.84 cells per million CD4 T-cells
Standard Deviation 626.39
|
361.05 cells per million CD4 T-cells
Standard Deviation 490.66
|
425.72 cells per million CD4 T-cells
Standard Deviation 346.49
|
471.70 cells per million CD4 T-cells
Standard Deviation 566.40
|
353.82 cells per million CD4 T-cells
Standard Deviation 432.84
|
234.90 cells per million CD4 T-cells
Standard Deviation 304.83
|
690.69 cells per million CD4 T-cells
Standard Deviation 642.61
|
999.02 cells per million CD4 T-cells
Standard Deviation 831.24
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD4-CD40L]
|
733.96 cells per million CD4 T-cells
Standard Deviation 397.17
|
576.04 cells per million CD4 T-cells
Standard Deviation 543.29
|
682.43 cells per million CD4 T-cells
Standard Deviation 823.68
|
439.97 cells per million CD4 T-cells
Standard Deviation 825.94
|
680.00 cells per million CD4 T-cells
Standard Deviation 607.45
|
683.28 cells per million CD4 T-cells
Standard Deviation 761.14
|
623.11 cells per million CD4 T-cells
Standard Deviation 800.89
|
554.83 cells per million CD4 T-cells
Standard Deviation 502.42
|
625.97 cells per million CD4 T-cells
Standard Deviation 924.73
|
1268.21 cells per million CD4 T-cells
Standard Deviation 889.54
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD4-CD40L]
|
621.50 cells per million CD4 T-cells
Standard Deviation 3427.50
|
764.21 cells per million CD4 T-cells
Standard Deviation 613.38
|
779.35 cells per million CD4 T-cells
Standard Deviation 887.41
|
394.05 cells per million CD4 T-cells
Standard Deviation 415.93
|
743.85 cells per million CD4 T-cells
Standard Deviation 425.01
|
414.76 cells per million CD4 T-cells
Standard Deviation 732.26
|
592.52 cells per million CD4 T-cells
Standard Deviation 424.79
|
537.41 cells per million CD4 T-cells
Standard Deviation 351.86
|
679.16 cells per million CD4 T-cells
Standard Deviation 486.34
|
1260.62 cells per million CD4 T-cells
Standard Deviation 1067.54
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD4-IFNγ]
|
244.53 cells per million CD4 T-cells
Standard Deviation 325.64
|
375.03 cells per million CD4 T-cells
Standard Deviation 308.38
|
392.18 cells per million CD4 T-cells
Standard Deviation 500.72
|
280.73 cells per million CD4 T-cells
Standard Deviation 402.63
|
261.43 cells per million CD4 T-cells
Standard Deviation 263.15
|
338.11 cells per million CD4 T-cells
Standard Deviation 488.06
|
271.38 cells per million CD4 T-cells
Standard Deviation 373.04
|
136.97 cells per million CD4 T-cells
Standard Deviation 262.56
|
445.44 cells per million CD4 T-cells
Standard Deviation 577.53
|
867.78 cells per million CD4 T-cells
Standard Deviation 658.04
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD4-IFNγ]
|
492.75 cells per million CD4 T-cells
Standard Deviation 320.15
|
476.37 cells per million CD4 T-cells
Standard Deviation 416.85
|
548.14 cells per million CD4 T-cells
Standard Deviation 557.60
|
372.77 cells per million CD4 T-cells
Standard Deviation 618.70
|
399.91 cells per million CD4 T-cells
Standard Deviation 481.00
|
325.70 cells per million CD4 T-cells
Standard Deviation 547.57
|
523.69 cells per million CD4 T-cells
Standard Deviation 683.65
|
374.66 cells per million CD4 T-cells
Standard Deviation 407.51
|
467.74 cells per million CD4 T-cells
Standard Deviation 807.28
|
971.26 cells per million CD4 T-cells
Standard Deviation 783.42
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD4-IFNγ]
|
522.75 cells per million CD4 T-cells
Standard Deviation 3348.47
|
510.43 cells per million CD4 T-cells
Standard Deviation 462.45
|
457.89 cells per million CD4 T-cells
Standard Deviation 774.10
|
253.06 cells per million CD4 T-cells
Standard Deviation 234.64
|
411.84 cells per million CD4 T-cells
Standard Deviation 384.77
|
240.48 cells per million CD4 T-cells
Standard Deviation 567.12
|
361.94 cells per million CD4 T-cells
Standard Deviation 357.95
|
360.90 cells per million CD4 T-cells
Standard Deviation 250.90
|
458.80 cells per million CD4 T-cells
Standard Deviation 456.80
|
1073.05 cells per million CD4 T-cells
Standard Deviation 935.35
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD4-IL2]
|
316.88 cells per million CD4 T-cells
Standard Deviation 297.00
|
314.96 cells per million CD4 T-cells
Standard Deviation 372.22
|
558.83 cells per million CD4 T-cells
Standard Deviation 549.83
|
304.00 cells per million CD4 T-cells
Standard Deviation 404.11
|
368.31 cells per million CD4 T-cells
Standard Deviation 348.92
|
400.05 cells per million CD4 T-cells
Standard Deviation 505.26
|
304.33 cells per million CD4 T-cells
Standard Deviation 467.47
|
175.36 cells per million CD4 T-cells
Standard Deviation 258.68
|
691.47 cells per million CD4 T-cells
Standard Deviation 597.60
|
859.06 cells per million CD4 T-cells
Standard Deviation 642.57
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD4-IL2]
|
579.40 cells per million CD4 T-cells
Standard Deviation 330.85
|
426.54 cells per million CD4 T-cells
Standard Deviation 422.19
|
529.59 cells per million CD4 T-cells
Standard Deviation 677.44
|
480.46 cells per million CD4 T-cells
Standard Deviation 667.59
|
603.02 cells per million CD4 T-cells
Standard Deviation 608.61
|
551.29 cells per million CD4 T-cells
Standard Deviation 712.29
|
489.69 cells per million CD4 T-cells
Standard Deviation 841.98
|
339.94 cells per million CD4 T-cells
Standard Deviation 440.33
|
700.87 cells per million CD4 T-cells
Standard Deviation 861.25
|
1011.95 cells per million CD4 T-cells
Standard Deviation 565.94
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD4-IL2]
|
549.00 cells per million CD4 T-cells
Standard Deviation 2767.21
|
617.40 cells per million CD4 T-cells
Standard Deviation 602.01
|
698.16 cells per million CD4 T-cells
Standard Deviation 823.21
|
315.90 cells per million CD4 T-cells
Standard Deviation 393.50
|
672.69 cells per million CD4 T-cells
Standard Deviation 432.34
|
373.28 cells per million CD4 T-cells
Standard Deviation 680.43
|
518.17 cells per million CD4 T-cells
Standard Deviation 374.93
|
345.05 cells per million CD4 T-cells
Standard Deviation 300.46
|
612.61 cells per million CD4 T-cells
Standard Deviation 455.63
|
1119.01 cells per million CD4 T-cells
Standard Deviation 801.11
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD4-TNFα]
|
280.19 cells per million CD4 T-cells
Standard Deviation 284.35
|
188.48 cells per million CD4 T-cells
Standard Deviation 325.58
|
382.50 cells per million CD4 T-cells
Standard Deviation 490.32
|
200.30 cells per million CD4 T-cells
Standard Deviation 422.18
|
263.40 cells per million CD4 T-cells
Standard Deviation 301.07
|
350.38 cells per million CD4 T-cells
Standard Deviation 473.03
|
254.19 cells per million CD4 T-cells
Standard Deviation 373.61
|
228.89 cells per million CD4 T-cells
Standard Deviation 247.41
|
533.13 cells per million CD4 T-cells
Standard Deviation 517.19
|
730.49 cells per million CD4 T-cells
Standard Deviation 549.49
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD4-TNFα]
|
722.29 cells per million CD4 T-cells
Standard Deviation 288.16
|
600.27 cells per million CD4 T-cells
Standard Deviation 472.44
|
626.23 cells per million CD4 T-cells
Standard Deviation 655.14
|
395.86 cells per million CD4 T-cells
Standard Deviation 758.84
|
599.10 cells per million CD4 T-cells
Standard Deviation 496.66
|
512.38 cells per million CD4 T-cells
Standard Deviation 740.10
|
601.79 cells per million CD4 T-cells
Standard Deviation 703.08
|
561.14 cells per million CD4 T-cells
Standard Deviation 451.82
|
521.03 cells per million CD4 T-cells
Standard Deviation 873.58
|
1187.70 cells per million CD4 T-cells
Standard Deviation 734.12
|
|
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD4-TNFα]
|
538.21 cells per million CD4 T-cells
Standard Deviation 2445.31
|
576.09 cells per million CD4 T-cells
Standard Deviation 352.91
|
408.52 cells per million CD4 T-cells
Standard Deviation 712.70
|
149.41 cells per million CD4 T-cells
Standard Deviation 359.72
|
476.90 cells per million CD4 T-cells
Standard Deviation 332.91
|
160.26 cells per million CD4 T-cells
Standard Deviation 542.67
|
360.57 cells per million CD4 T-cells
Standard Deviation 367.88
|
385.22 cells per million CD4 T-cells
Standard Deviation 227.19
|
505.39 cells per million CD4 T-cells
Standard Deviation 393.49
|
798.97 cells per million CD4 T-cells
Standard Deviation 716.33
|
SECONDARY outcome
Timeframe: At Days 0 and 21Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.
The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=19 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=25 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=24 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=23 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=23 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=23 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-IL2] at Day 21
|
17.85 cells per million CD8 T-cells
Standard Deviation 257.14
|
32.92 cells per million CD8 T-cells
Standard Deviation 72.84
|
9.72 cells per million CD8 T-cells
Standard Deviation 118.83
|
4.83 cells per million CD8 T-cells
Standard Deviation 129.69
|
7.60 cells per million CD8 T-cells
Standard Deviation 27.90
|
8.49 cells per million CD8 T-cells
Standard Deviation 137.21
|
17.98 cells per million CD8 T-cells
Standard Deviation 127.27
|
5.19 cells per million CD8 T-cells
Standard Deviation 81.07
|
7.95 cells per million CD8 T-cells
Standard Deviation 75.16
|
12.46 cells per million CD8 T-cells
Standard Deviation 96.16
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-All doubles] at Day 21
|
31.08 cells per million CD8 T-cells
Standard Deviation 84.59
|
7.54 cells per million CD8 T-cells
Standard Deviation 234.23
|
9.77 cells per million CD8 T-cells
Standard Deviation 292.05
|
4.15 cells per million CD8 T-cells
Standard Deviation 66.82
|
7.73 cells per million CD8 T-cells
Standard Deviation 139.86
|
12.49 cells per million CD8 T-cells
Standard Deviation 189.06
|
16.86 cells per million CD8 T-cells
Standard Deviation 219.38
|
4.99 cells per million CD8 T-cells
Standard Deviation 168.28
|
39.03 cells per million CD8 T-cells
Standard Deviation 123.00
|
2.00 cells per million CD8 T-cells
Standard Deviation 57.24
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-All doubles] at Day 0
|
11.62 cells per million CD8 T-cells
Standard Deviation 200.31
|
15.68 cells per million CD8 T-cells
Standard Deviation 423.52
|
30.58 cells per million CD8 T-cells
Standard Deviation 282.37
|
10.85 cells per million CD8 T-cells
Standard Deviation 215.20
|
6.74 cells per million CD8 T-cells
Standard Deviation 63.87
|
2.48 cells per million CD8 T-cells
Standard Deviation 44.95
|
26.27 cells per million CD8 T-cells
Standard Deviation 218.28
|
23.57 cells per million CD8 T-cells
Standard Deviation 184.06
|
16.83 cells per million CD8 T-cells
Standard Deviation 232.88
|
11.02 cells per million CD8 T-cells
Standard Deviation 175.35
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-All doubles] at Day 21
|
42.50 cells per million CD8 T-cells
Standard Deviation 296.07
|
44.96 cells per million CD8 T-cells
Standard Deviation 351.05
|
20.54 cells per million CD8 T-cells
Standard Deviation 188.50
|
8.09 cells per million CD8 T-cells
Standard Deviation 302.34
|
31.02 cells per million CD8 T-cells
Standard Deviation 243.07
|
22.20 cells per million CD8 T-cells
Standard Deviation 183.56
|
60.96 cells per million CD8 T-cells
Standard Deviation 415.86
|
13.39 cells per million CD8 T-cells
Standard Deviation 193.75
|
24.91 cells per million CD8 T-cells
Standard Deviation 153.61
|
16.20 cells per million CD8 T-cells
Standard Deviation 225.18
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-CD40L] at Day 21
|
3.09 cells per million CD8 T-cells
Standard Deviation 45.67
|
5.72 cells per million CD8 T-cells
Standard Deviation 165.77
|
4.19 cells per million CD8 T-cells
Standard Deviation 52.99
|
3.00 cells per million CD8 T-cells
Standard Deviation 45.24
|
5.72 cells per million CD8 T-cells
Standard Deviation 90.85
|
5.01 cells per million CD8 T-cells
Standard Deviation 88.79
|
5.58 cells per million CD8 T-cells
Standard Deviation 98.17
|
5.17 cells per million CD8 T-cells
Standard Deviation 34.65
|
7.27 cells per million CD8 T-cells
Standard Deviation 43.58
|
2.04 cells per million CD8 T-cells
Standard Deviation 35.04
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-CD40L] at Day 21
|
2.68 cells per million CD8 T-cells
Standard Deviation 127.60
|
12.06 cells per million CD8 T-cells
Standard Deviation 265.01
|
3.74 cells per million CD8 T-cells
Standard Deviation 115.89
|
4.45 cells per million CD8 T-cells
Standard Deviation 142.55
|
9.13 cells per million CD8 T-cells
Standard Deviation 183.09
|
5.64 cells per million CD8 T-cells
Standard Deviation 138.31
|
8.97 cells per million CD8 T-cells
Standard Deviation 271.08
|
4.47 cells per million CD8 T-cells
Standard Deviation 183.70
|
3.43 cells per million CD8 T-cells
Standard Deviation 72.64
|
9.50 cells per million CD8 T-cells
Standard Deviation 127.97
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-All doubles] at Day 0
|
8.10 cells per million CD8 T-cells
Standard Deviation 135.40
|
12.90 cells per million CD8 T-cells
Standard Deviation 151.71
|
14.46 cells per million CD8 T-cells
Standard Deviation 122.65
|
3.25 cells per million CD8 T-cells
Standard Deviation 53.78
|
3.31 cells per million CD8 T-cells
Standard Deviation 91.60
|
2.31 cells per million CD8 T-cells
Standard Deviation 47.88
|
2.63 cells per million CD8 T-cells
Standard Deviation 98.13
|
6.83 cells per million CD8 T-cells
Standard Deviation 67.42
|
13.81 cells per million CD8 T-cells
Standard Deviation 116.94
|
7.69 cells per million CD8 T-cells
Standard Deviation 91.40
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-All doubles] at Day 21
|
7.45 cells per million CD8 T-cells
Standard Deviation 97.10
|
12.20 cells per million CD8 T-cells
Standard Deviation 127.89
|
9.54 cells per million CD8 T-cells
Standard Deviation 116.11
|
5.14 cells per million CD8 T-cells
Standard Deviation 87.63
|
4.87 cells per million CD8 T-cells
Standard Deviation 92.78
|
4.71 cells per million CD8 T-cells
Standard Deviation 49.37
|
9.62 cells per million CD8 T-cells
Standard Deviation 50.39
|
4.76 cells per million CD8 T-cells
Standard Deviation 132.76
|
6.33 cells per million CD8 T-cells
Standard Deviation 91.54
|
2.34 cells per million CD8 T-cells
Standard Deviation 132.36
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-All doubles] at Day 0
|
9.69 cells per million CD8 T-cells
Standard Deviation 178.06
|
6.81 cells per million CD8 T-cells
Standard Deviation 126.03
|
9.85 cells per million CD8 T-cells
Standard Deviation 344.91
|
3.93 cells per million CD8 T-cells
Standard Deviation 124.78
|
6.67 cells per million CD8 T-cells
Standard Deviation 112.61
|
5.53 cells per million CD8 T-cells
Standard Deviation 169.17
|
8.19 cells per million CD8 T-cells
Standard Deviation 95.91
|
6.73 cells per million CD8 T-cells
Standard Deviation 108.10
|
8.22 cells per million CD8 T-cells
Standard Deviation 153.57
|
9.16 cells per million CD8 T-cells
Standard Deviation 63.84
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-CD40L] at Day 0
|
7.68 cells per million CD8 T-cells
Standard Deviation 76.49
|
9.18 cells per million CD8 T-cells
Standard Deviation 141.09
|
7.64 cells per million CD8 T-cells
Standard Deviation 81.73
|
2.31 cells per million CD8 T-cells
Standard Deviation 25.28
|
2.75 cells per million CD8 T-cells
Standard Deviation 106.31
|
1.47 cells per million CD8 T-cells
Standard Deviation 26.08
|
2.39 cells per million CD8 T-cells
Standard Deviation 55.56
|
2.94 cells per million CD8 T-cells
Standard Deviation 67.71
|
10.48 cells per million CD8 T-cells
Standard Deviation 95.48
|
2.70 cells per million CD8 T-cells
Standard Deviation 77.94
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-CD40L] at Day 21
|
3.76 cells per million CD8 T-cells
Standard Deviation 69.81
|
3.41 cells per million CD8 T-cells
Standard Deviation 98.02
|
8.71 cells per million CD8 T-cells
Standard Deviation 75.81
|
2.20 cells per million CD8 T-cells
Standard Deviation 47.58
|
3.22 cells per million CD8 T-cells
Standard Deviation 72.42
|
2.21 cells per million CD8 T-cells
Standard Deviation 42.86
|
3.36 cells per million CD8 T-cells
Standard Deviation 55.81
|
3.45 cells per million CD8 T-cells
Standard Deviation 82.08
|
2.30 cells per million CD8 T-cells
Standard Deviation 53.40
|
2.97 cells per million CD8 T-cells
Standard Deviation 43.37
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-CD40L] at Day 0
|
4.63 cells per million CD8 T-cells
Standard Deviation 51.86
|
2.17 cells per million CD8 T-cells
Standard Deviation 41.97
|
5.20 cells per million CD8 T-cells
Standard Deviation 70.37
|
1.82 cells per million CD8 T-cells
Standard Deviation 70.40
|
2.78 cells per million CD8 T-cells
Standard Deviation 66.95
|
1.47 cells per million CD8 T-cells
Standard Deviation 26.82
|
3.10 cells per million CD8 T-cells
Standard Deviation 43.93
|
2.08 cells per million CD8 T-cells
Standard Deviation 53.94
|
4.55 cells per million CD8 T-cells
Standard Deviation 93.16
|
2.96 cells per million CD8 T-cells
Standard Deviation 99.03
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-CD40L] at Day 0
|
3.24 cells per million CD8 T-cells
Standard Deviation 54.73
|
7.16 cells per million CD8 T-cells
Standard Deviation 290.97
|
6.53 cells per million CD8 T-cells
Standard Deviation 132.89
|
2.82 cells per million CD8 T-cells
Standard Deviation 87.95
|
2.84 cells per million CD8 T-cells
Standard Deviation 47.37
|
1.66 cells per million CD8 T-cells
Standard Deviation 34.20
|
3.29 cells per million CD8 T-cells
Standard Deviation 76.69
|
5.21 cells per million CD8 T-cells
Standard Deviation 59.00
|
5.52 cells per million CD8 T-cells
Standard Deviation 168.72
|
3.98 cells per million CD8 T-cells
Standard Deviation 95.04
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-IFNγ] at Day 0
|
7.38 cells per million CD8 T-cells
Standard Deviation 115.60
|
8.63 cells per million CD8 T-cells
Standard Deviation 157.70
|
10.16 cells per million CD8 T-cells
Standard Deviation 107.21
|
3.99 cells per million CD8 T-cells
Standard Deviation 62.89
|
4.69 cells per million CD8 T-cells
Standard Deviation 90.75
|
1.89 cells per million CD8 T-cells
Standard Deviation 57.50
|
3.04 cells per million CD8 T-cells
Standard Deviation 89.37
|
6.83 cells per million CD8 T-cells
Standard Deviation 63.62
|
8.68 cells per million CD8 T-cells
Standard Deviation 98.54
|
4.59 cells per million CD8 T-cells
Standard Deviation 65.86
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-IFNγ] at Day 21
|
7.37 cells per million CD8 T-cells
Standard Deviation 84.04
|
9.19 cells per million CD8 T-cells
Standard Deviation 85.93
|
11.15 cells per million CD8 T-cells
Standard Deviation 94.57
|
2.18 cells per million CD8 T-cells
Standard Deviation 51.19
|
3.96 cells per million CD8 T-cells
Standard Deviation 75.52
|
2.03 cells per million CD8 T-cells
Standard Deviation 23.00
|
5.60 cells per million CD8 T-cells
Standard Deviation 50.57
|
3.18 cells per million CD8 T-cells
Standard Deviation 106.55
|
3.25 cells per million CD8 T-cells
Standard Deviation 64.56
|
1.59 cells per million CD8 T-cells
Standard Deviation 141.41
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-IFNγ] at Day 0
|
7.85 cells per million CD8 T-cells
Standard Deviation 103.62
|
3.95 cells per million CD8 T-cells
Standard Deviation 78.12
|
7.61 cells per million CD8 T-cells
Standard Deviation 309.89
|
2.46 cells per million CD8 T-cells
Standard Deviation 120.14
|
5.23 cells per million CD8 T-cells
Standard Deviation 75.71
|
2.51 cells per million CD8 T-cells
Standard Deviation 168.10
|
4.70 cells per million CD8 T-cells
Standard Deviation 53.61
|
4.05 cells per million CD8 T-cells
Standard Deviation 52.57
|
7.23 cells per million CD8 T-cells
Standard Deviation 129.33
|
7.26 cells per million CD8 T-cells
Standard Deviation 64.60
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-IFNγ] at Day 21
|
8.27 cells per million CD8 T-cells
Standard Deviation 78.96
|
8.63 cells per million CD8 T-cells
Standard Deviation 176.22
|
9.89 cells per million CD8 T-cells
Standard Deviation 295.99
|
3.52 cells per million CD8 T-cells
Standard Deviation 66.86
|
6.18 cells per million CD8 T-cells
Standard Deviation 125.90
|
10.28 cells per million CD8 T-cells
Standard Deviation 119.10
|
12.07 cells per million CD8 T-cells
Standard Deviation 140.10
|
4.02 cells per million CD8 T-cells
Standard Deviation 92.71
|
6.94 cells per million CD8 T-cells
Standard Deviation 109.72
|
2.21 cells per million CD8 T-cells
Standard Deviation 47.90
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-IFNγ] at Day 0
|
5.56 cells per million CD8 T-cells
Standard Deviation 99.28
|
10.71 cells per million CD8 T-cells
Standard Deviation 390.44
|
15.15 cells per million CD8 T-cells
Standard Deviation 261.46
|
6.09 cells per million CD8 T-cells
Standard Deviation 157.93
|
10.28 cells per million CD8 T-cells
Standard Deviation 61.17
|
1.69 cells per million CD8 T-cells
Standard Deviation 19.96
|
17.27 cells per million CD8 T-cells
Standard Deviation 129.27
|
17.76 cells per million CD8 T-cells
Standard Deviation 137.26
|
9.94 cells per million CD8 T-cells
Standard Deviation 190.65
|
9.07 cells per million CD8 T-cells
Standard Deviation 168.50
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-IFNγ] at Day 21
|
11.69 cells per million CD8 T-cells
Standard Deviation 129.41
|
17.80 cells per million CD8 T-cells
Standard Deviation 305.22
|
14.44 cells per million CD8 T-cells
Standard Deviation 160.52
|
5.42 cells per million CD8 T-cells
Standard Deviation 269.73
|
14.05 cells per million CD8 T-cells
Standard Deviation 224.41
|
9.75 cells per million CD8 T-cells
Standard Deviation 159.06
|
23.95 cells per million CD8 T-cells
Standard Deviation 323.71
|
18.53 cells per million CD8 T-cells
Standard Deviation 162.45
|
21.99 cells per million CD8 T-cells
Standard Deviation 122.96
|
12.44 cells per million CD8 T-cells
Standard Deviation 163.33
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-IL2] at Day 0
|
3.52 cells per million CD8 T-cells
Standard Deviation 80.50
|
3.10 cells per million CD8 T-cells
Standard Deviation 27.39
|
5.50 cells per million CD8 T-cells
Standard Deviation 55.47
|
3.03 cells per million CD8 T-cells
Standard Deviation 42.10
|
1.20 cells per million CD8 T-cells
Standard Deviation 13.14
|
2.12 cells per million CD8 T-cells
Standard Deviation 30.13
|
3.28 cells per million CD8 T-cells
Standard Deviation 81.61
|
2.96 cells per million CD8 T-cells
Standard Deviation 40.40
|
4.00 cells per million CD8 T-cells
Standard Deviation 42.26
|
2.67 cells per million CD8 T-cells
Standard Deviation 38.98
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-IL2] at Day 21
|
4.80 cells per million CD8 T-cells
Standard Deviation 63.95
|
4.30 cells per million CD8 T-cells
Standard Deviation 73.39
|
7.50 cells per million CD8 T-cells
Standard Deviation 51.96
|
3.97 cells per million CD8 T-cells
Standard Deviation 61.17
|
1.98 cells per million CD8 T-cells
Standard Deviation 40.41
|
4.86 cells per million CD8 T-cells
Standard Deviation 57.41
|
4.36 cells per million CD8 T-cells
Standard Deviation 36.32
|
5.57 cells per million CD8 T-cells
Standard Deviation 83.12
|
7.30 cells per million CD8 T-cells
Standard Deviation 69.21
|
2.17 cells per million CD8 T-cells
Standard Deviation 44.90
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-IL2] at Day 0
|
3.70 cells per million CD8 T-cells
Standard Deviation 113.92
|
3.21 cells per million CD8 T-cells
Standard Deviation 91.01
|
6.13 cells per million CD8 T-cells
Standard Deviation 99.85
|
3.13 cells per million CD8 T-cells
Standard Deviation 61.75
|
2.11 cells per million CD8 T-cells
Standard Deviation 71.74
|
4.05 cells per million CD8 T-cells
Standard Deviation 62.37
|
5.41 cells per million CD8 T-cells
Standard Deviation 65.29
|
6.43 cells per million CD8 T-cells
Standard Deviation 82.32
|
3.75 cells per million CD8 T-cells
Standard Deviation 71.92
|
2.00 cells per million CD8 T-cells
Standard Deviation 23.96
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-IL2] at Day 21
|
12.45 cells per million CD8 T-cells
Standard Deviation 89.54
|
5.93 cells per million CD8 T-cells
Standard Deviation 78.91
|
7.70 cells per million CD8 T-cells
Standard Deviation 64.46
|
3.05 cells per million CD8 T-cells
Standard Deviation 40.35
|
2.97 cells per million CD8 T-cells
Standard Deviation 61.70
|
4.41 cells per million CD8 T-cells
Standard Deviation 109.49
|
10.92 cells per million CD8 T-cells
Standard Deviation 109.83
|
6.18 cells per million CD8 T-cells
Standard Deviation 125.87
|
14.11 cells per million CD8 T-cells
Standard Deviation 81.52
|
2.69 cells per million CD8 T-cells
Standard Deviation 51.22
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-IL2] at Day 0
|
8.66 cells per million CD8 T-cells
Standard Deviation 147.36
|
4.40 cells per million CD8 T-cells
Standard Deviation 161.85
|
10.05 cells per million CD8 T-cells
Standard Deviation 141.49
|
9.50 cells per million CD8 T-cells
Standard Deviation 106.18
|
2.13 cells per million CD8 T-cells
Standard Deviation 22.15
|
2.66 cells per million CD8 T-cells
Standard Deviation 49.28
|
12.10 cells per million CD8 T-cells
Standard Deviation 182.42
|
17.14 cells per million CD8 T-cells
Standard Deviation 88.20
|
6.41 cells per million CD8 T-cells
Standard Deviation 108.44
|
2.17 cells per million CD8 T-cells
Standard Deviation 64.13
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-TNFα] at Day 0
|
5.41 cells per million CD8 T-cells
Standard Deviation 91.54
|
3.26 cells per million CD8 T-cells
Standard Deviation 34.12
|
8.71 cells per million CD8 T-cells
Standard Deviation 71.14
|
2.59 cells per million CD8 T-cells
Standard Deviation 42.20
|
2.58 cells per million CD8 T-cells
Standard Deviation 39.14
|
2.28 cells per million CD8 T-cells
Standard Deviation 45.26
|
2.18 cells per million CD8 T-cells
Standard Deviation 33.72
|
5.63 cells per million CD8 T-cells
Standard Deviation 58.18
|
3.94 cells per million CD8 T-cells
Standard Deviation 52.44
|
4.33 cells per million CD8 T-cells
Standard Deviation 81.83
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Solomon Islands [CD8-TNFα] at Day 21
|
3.79 cells per million CD8 T-cells
Standard Deviation 79.93
|
12.15 cells per million CD8 T-cells
Standard Deviation 70.97
|
2.76 cells per million CD8 T-cells
Standard Deviation 117.87
|
5.85 cells per million CD8 T-cells
Standard Deviation 65.60
|
2.68 cells per million CD8 T-cells
Standard Deviation 61.45
|
3.78 cells per million CD8 T-cells
Standard Deviation 51.36
|
5.33 cells per million CD8 T-cells
Standard Deviation 36.95
|
6.03 cells per million CD8 T-cells
Standard Deviation 110.26
|
4.35 cells per million CD8 T-cells
Standard Deviation 64.50
|
1.91 cells per million CD8 T-cells
Standard Deviation 131.67
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-TNFα] at Day 0
|
5.04 cells per million CD8 T-cells
Standard Deviation 145.40
|
3.70 cells per million CD8 T-cells
Standard Deviation 138.04
|
5.31 cells per million CD8 T-cells
Standard Deviation 338.73
|
3.70 cells per million CD8 T-cells
Standard Deviation 67.70
|
8.64 cells per million CD8 T-cells
Standard Deviation 86.13
|
9.54 cells per million CD8 T-cells
Standard Deviation 187.33
|
5.96 cells per million CD8 T-cells
Standard Deviation 128.54
|
10.06 cells per million CD8 T-cells
Standard Deviation 78.63
|
3.93 cells per million CD8 T-cells
Standard Deviation 93.43
|
3.41 cells per million CD8 T-cells
Standard Deviation 64.37
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
A/Wisconsin [CD8-TNFα] at Day 21
|
14.64 cells per million CD8 T-cells
Standard Deviation 98.80
|
5.75 cells per million CD8 T-cells
Standard Deviation 118.21
|
5.74 cells per million CD8 T-cells
Standard Deviation 278.42
|
3.47 cells per million CD8 T-cells
Standard Deviation 65.17
|
5.60 cells per million CD8 T-cells
Standard Deviation 66.01
|
12.32 cells per million CD8 T-cells
Standard Deviation 188.66
|
11.29 cells per million CD8 T-cells
Standard Deviation 211.80
|
8.52 cells per million CD8 T-cells
Standard Deviation 135.47
|
16.28 cells per million CD8 T-cells
Standard Deviation 142.20
|
2.52 cells per million CD8 T-cells
Standard Deviation 46.95
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-TNFα] at Day 0
|
11.49 cells per million CD8 T-cells
Standard Deviation 167.40
|
11.28 cells per million CD8 T-cells
Standard Deviation 215.17
|
18.47 cells per million CD8 T-cells
Standard Deviation 194.16
|
8.77 cells per million CD8 T-cells
Standard Deviation 177.85
|
6.77 cells per million CD8 T-cells
Standard Deviation 50.82
|
2.67 cells per million CD8 T-cells
Standard Deviation 37.22
|
26.25 cells per million CD8 T-cells
Standard Deviation 172.19
|
23.27 cells per million CD8 T-cells
Standard Deviation 109.52
|
14.97 cells per million CD8 T-cells
Standard Deviation 169.37
|
9.07 cells per million CD8 T-cells
Standard Deviation 123.64
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
B/Malaysia [CD8-TNFα] at Day 21
|
28.50 cells per million CD8 T-cells
Standard Deviation 261.61
|
13.76 cells per million CD8 T-cells
Standard Deviation 122.97
|
9.28 cells per million CD8 T-cells
Standard Deviation 142.76
|
9.21 cells per million CD8 T-cells
Standard Deviation 224.57
|
15.20 cells per million CD8 T-cells
Standard Deviation 160.37
|
9.02 cells per million CD8 T-cells
Standard Deviation 96.93
|
27.84 cells per million CD8 T-cells
Standard Deviation 355.89
|
15.64 cells per million CD8 T-cells
Standard Deviation 126.07
|
19.42 cells per million CD8 T-cells
Standard Deviation 124.13
|
8.57 cells per million CD8 T-cells
Standard Deviation 151.66
|
SECONDARY outcome
Timeframe: At Day 180Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.
The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=21 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=18 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=20 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=17 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=21 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=20 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=19 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=16 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=16 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=19 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD8-All doubles]
|
9.92 cells per million CD8 T-cells
Standard Deviation 111.75
|
7.10 cells per million CD8 T-cells
Standard Deviation 132.35
|
12.14 cells per million CD8 T-cells
Standard Deviation 319.23
|
9.61 cells per million CD8 T-cells
Standard Deviation 157.68
|
25.48 cells per million CD8 T-cells
Standard Deviation 138.45
|
9.18 cells per million CD8 T-cells
Standard Deviation 143.21
|
12.73 cells per million CD8 T-cells
Standard Deviation 460.97
|
4.71 cells per million CD8 T-cells
Standard Deviation 115.31
|
6.47 cells per million CD8 T-cells
Standard Deviation 83.62
|
7.96 cells per million CD8 T-cells
Standard Deviation 132.07
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD8-IL2]
|
20.60 cells per million CD8 T-cells
Standard Deviation 427.25
|
15.24 cells per million CD8 T-cells
Standard Deviation 108.11
|
14.05 cells per million CD8 T-cells
Standard Deviation 351.12
|
42.75 cells per million CD8 T-cells
Standard Deviation 112.35
|
19.37 cells per million CD8 T-cells
Standard Deviation 415.28
|
32.48 cells per million CD8 T-cells
Standard Deviation 357.67
|
15.96 cells per million CD8 T-cells
Standard Deviation 296.44
|
11.89 cells per million CD8 T-cells
Standard Deviation 385.26
|
10.37 cells per million CD8 T-cells
Standard Deviation 212.91
|
4.04 cells per million CD8 T-cells
Standard Deviation 153.21
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD8-All doubles]
|
2.57 cells per million CD8 T-cells
Standard Deviation 89.78
|
14.64 cells per million CD8 T-cells
Standard Deviation 96.62
|
3.61 cells per million CD8 T-cells
Standard Deviation 143.10
|
4.75 cells per million CD8 T-cells
Standard Deviation 74.09
|
3.05 cells per million CD8 T-cells
Standard Deviation 107.06
|
1.24 cells per million CD8 T-cells
Standard Deviation 15.43
|
2.64 cells per million CD8 T-cells
Standard Deviation 47.18
|
4.81 cells per million CD8 T-cells
Standard Deviation 90.76
|
7.32 cells per million CD8 T-cells
Standard Deviation 115.74
|
5.64 cells per million CD8 T-cells
Standard Deviation 98.76
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD8-All doubles]
|
21.14 cells per million CD8 T-cells
Standard Deviation 506.65
|
9.63 cells per million CD8 T-cells
Standard Deviation 110.40
|
18.10 cells per million CD8 T-cells
Standard Deviation 367.31
|
16.14 cells per million CD8 T-cells
Standard Deviation 132.83
|
20.72 cells per million CD8 T-cells
Standard Deviation 412.35
|
21.73 cells per million CD8 T-cells
Standard Deviation 368.70
|
21.00 cells per million CD8 T-cells
Standard Deviation 327.24
|
11.95 cells per million CD8 T-cells
Standard Deviation 384.28
|
10.44 cells per million CD8 T-cells
Standard Deviation 226.57
|
3.13 cells per million CD8 T-cells
Standard Deviation 186.12
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD8-CD40L]
|
2.92 cells per million CD8 T-cells
Standard Deviation 53.08
|
12.64 cells per million CD8 T-cells
Standard Deviation 119.84
|
2.95 cells per million CD8 T-cells
Standard Deviation 97.98
|
3.18 cells per million CD8 T-cells
Standard Deviation 74.24
|
3.97 cells per million CD8 T-cells
Standard Deviation 69.10
|
1.93 cells per million CD8 T-cells
Standard Deviation 31.31
|
2.70 cells per million CD8 T-cells
Standard Deviation 59.56
|
4.89 cells per million CD8 T-cells
Standard Deviation 86.67
|
8.74 cells per million CD8 T-cells
Standard Deviation 100.11
|
3.94 cells per million CD8 T-cells
Standard Deviation 40.79
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD8-CD40L]
|
18.75 cells per million CD8 T-cells
Standard Deviation 312.61
|
7.79 cells per million CD8 T-cells
Standard Deviation 60.25
|
10.73 cells per million CD8 T-cells
Standard Deviation 230.49
|
15.32 cells per million CD8 T-cells
Standard Deviation 145.70
|
9.60 cells per million CD8 T-cells
Standard Deviation 232.78
|
8.57 cells per million CD8 T-cells
Standard Deviation 321.14
|
13.90 cells per million CD8 T-cells
Standard Deviation 118.80
|
6.00 cells per million CD8 T-cells
Standard Deviation 315.87
|
6.46 cells per million CD8 T-cells
Standard Deviation 135.88
|
3.43 cells per million CD8 T-cells
Standard Deviation 66.51
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD8-CD40L]
|
5.79 cells per million CD8 T-cells
Standard Deviation 103.71
|
5.64 cells per million CD8 T-cells
Standard Deviation 75.90
|
10.61 cells per million CD8 T-cells
Standard Deviation 125.46
|
7.48 cells per million CD8 T-cells
Standard Deviation 92.38
|
8.46 cells per million CD8 T-cells
Standard Deviation 105.02
|
6.10 cells per million CD8 T-cells
Standard Deviation 113.43
|
3.77 cells per million CD8 T-cells
Standard Deviation 59.02
|
2.75 cells per million CD8 T-cells
Standard Deviation 73.05
|
3.63 cells per million CD8 T-cells
Standard Deviation 81.37
|
3.78 cells per million CD8 T-cells
Standard Deviation 95.38
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD8-IFNγ]
|
2.00 cells per million CD8 T-cells
Standard Deviation 54.66
|
3.12 cells per million CD8 T-cells
Standard Deviation 124.76
|
3.13 cells per million CD8 T-cells
Standard Deviation 50.16
|
3.89 cells per million CD8 T-cells
Standard Deviation 53.23
|
1.90 cells per million CD8 T-cells
Standard Deviation 35.38
|
3.12 cells per million CD8 T-cells
Standard Deviation 47.02
|
3.07 cells per million CD8 T-cells
Standard Deviation 31.51
|
3.11 cells per million CD8 T-cells
Standard Deviation 45.39
|
2.36 cells per million CD8 T-cells
Standard Deviation 55.08
|
2.65 cells per million CD8 T-cells
Standard Deviation 79.58
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD8-IFNγ]
|
4.21 cells per million CD8 T-cells
Standard Deviation 167.18
|
2.68 cells per million CD8 T-cells
Standard Deviation 42.60
|
2.32 cells per million CD8 T-cells
Standard Deviation 92.50
|
2.89 cells per million CD8 T-cells
Standard Deviation 43.98
|
2.50 cells per million CD8 T-cells
Standard Deviation 53.46
|
2.53 cells per million CD8 T-cells
Standard Deviation 46.46
|
2.39 cells per million CD8 T-cells
Standard Deviation 154.17
|
3.67 cells per million CD8 T-cells
Standard Deviation 78.90
|
1.97 cells per million CD8 T-cells
Standard Deviation 157.41
|
2.72 cells per million CD8 T-cells
Standard Deviation 125.70
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD8-IFNγ]
|
10.63 cells per million CD8 T-cells
Standard Deviation 76.06
|
3.72 cells per million CD8 T-cells
Standard Deviation 66.40
|
6.46 cells per million CD8 T-cells
Standard Deviation 183.07
|
6.19 cells per million CD8 T-cells
Standard Deviation 170.54
|
10.24 cells per million CD8 T-cells
Standard Deviation 49.87
|
4.96 cells per million CD8 T-cells
Standard Deviation 55.70
|
8.54 cells per million CD8 T-cells
Standard Deviation 430.43
|
2.56 cells per million CD8 T-cells
Standard Deviation 40.61
|
4.12 cells per million CD8 T-cells
Standard Deviation 49.87
|
5.33 cells per million CD8 T-cells
Standard Deviation 182.33
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD8-IL2]
|
1.97 cells per million CD8 T-cells
Standard Deviation 64.78
|
10.49 cells per million CD8 T-cells
Standard Deviation 74.37
|
2.82 cells per million CD8 T-cells
Standard Deviation 105.05
|
3.36 cells per million CD8 T-cells
Standard Deviation 44.53
|
3.76 cells per million CD8 T-cells
Standard Deviation 68.56
|
1.89 cells per million CD8 T-cells
Standard Deviation 25.49
|
4.31 cells per million CD8 T-cells
Standard Deviation 70.92
|
4.89 cells per million CD8 T-cells
Standard Deviation 86.67
|
4.93 cells per million CD8 T-cells
Standard Deviation 111.36
|
7.15 cells per million CD8 T-cells
Standard Deviation 75.19
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD8-IL2]
|
4.15 cells per million CD8 T-cells
Standard Deviation 92.98
|
7.59 cells per million CD8 T-cells
Standard Deviation 100.66
|
11.05 cells per million CD8 T-cells
Standard Deviation 217.46
|
7.47 cells per million CD8 T-cells
Standard Deviation 77.13
|
11.50 cells per million CD8 T-cells
Standard Deviation 130.60
|
11.62 cells per million CD8 T-cells
Standard Deviation 176.05
|
3.86 cells per million CD8 T-cells
Standard Deviation 81.13
|
5.99 cells per million CD8 T-cells
Standard Deviation 110.92
|
4.38 cells per million CD8 T-cells
Standard Deviation 95.85
|
6.11 cells per million CD8 T-cells
Standard Deviation 91.97
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Solomon Islands [CD8-TNFα]
|
2.54 cells per million CD8 T-cells
Standard Deviation 60.55
|
2.35 cells per million CD8 T-cells
Standard Deviation 31.14
|
2.09 cells per million CD8 T-cells
Standard Deviation 62.82
|
3.60 cells per million CD8 T-cells
Standard Deviation 37.07
|
1.62 cells per million CD8 T-cells
Standard Deviation 76.42
|
1.53 cells per million CD8 T-cells
Standard Deviation 21.24
|
2.44 cells per million CD8 T-cells
Standard Deviation 28.80
|
2.73 cells per million CD8 T-cells
Standard Deviation 44.50
|
2.54 cells per million CD8 T-cells
Standard Deviation 79.84
|
3.39 cells per million CD8 T-cells
Standard Deviation 69.30
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
A/Wisconsin [CD8-TNFα]
|
7.78 cells per million CD8 T-cells
Standard Deviation 244.26
|
4.42 cells per million CD8 T-cells
Standard Deviation 63.49
|
9.25 cells per million CD8 T-cells
Standard Deviation 151.69
|
6.69 cells per million CD8 T-cells
Standard Deviation 85.85
|
6.67 cells per million CD8 T-cells
Standard Deviation 210.64
|
3.26 cells per million CD8 T-cells
Standard Deviation 108.02
|
9.09 cells per million CD8 T-cells
Standard Deviation 213.44
|
4.86 cells per million CD8 T-cells
Standard Deviation 78.63
|
6.81 cells per million CD8 T-cells
Standard Deviation 139.38
|
3.52 cells per million CD8 T-cells
Standard Deviation 125.46
|
|
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
B/Malaysia [CD8-TNFα]
|
4.05 cells per million CD8 T-cells
Standard Deviation 74.16
|
5.66 cells per million CD8 T-cells
Standard Deviation 88.74
|
14.08 cells per million CD8 T-cells
Standard Deviation 191.59
|
3.84 cells per million CD8 T-cells
Standard Deviation 93.04
|
6.11 cells per million CD8 T-cells
Standard Deviation 48.41
|
5.46 cells per million CD8 T-cells
Standard Deviation 88.95
|
5.07 cells per million CD8 T-cells
Standard Deviation 415.90
|
3.63 cells per million CD8 T-cells
Standard Deviation 81.27
|
4.69 cells per million CD8 T-cells
Standard Deviation 42.36
|
4.58 cells per million CD8 T-cells
Standard Deviation 132.21
|
SECONDARY outcome
Timeframe: During a 7-day follow-up period (Day 0-6) after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. \> 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was \>20mm.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=197 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=201 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Any ecchymosis
|
3 Subjects
|
1 Subjects
|
5 Subjects
|
1 Subjects
|
2 Subjects
|
2 Subjects
|
4 Subjects
|
2 Subjects
|
3 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 ecchymosis
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Any pain
|
68 Subjects
|
82 Subjects
|
111 Subjects
|
84 Subjects
|
91 Subjects
|
119 Subjects
|
93 Subjects
|
106 Subjects
|
32 Subjects
|
93 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 pain
|
1 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
2 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Any redness
|
15 Subjects
|
16 Subjects
|
37 Subjects
|
12 Subjects
|
33 Subjects
|
36 Subjects
|
18 Subjects
|
34 Subjects
|
5 Subjects
|
2 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 redness
|
0 Subjects
|
1 Subjects
|
3 Subjects
|
1 Subjects
|
1 Subjects
|
2 Subjects
|
0 Subjects
|
2 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Any swelling
|
13 Subjects
|
12 Subjects
|
25 Subjects
|
13 Subjects
|
18 Subjects
|
23 Subjects
|
11 Subjects
|
25 Subjects
|
5 Subjects
|
2 Subjects
|
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 swelling
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
1 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
SECONDARY outcome
Timeframe: During a 7-day follow-up period (Day 0-6) after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.
Duration was defined as number of days with any grade of local symptoms.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=68 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=82 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=111 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=84 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=91 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=119 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=93 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=106 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=32 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=93 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Solicited Local AEs
Swelling (N=12;12;24;12;17;23;11;25;5;2)
|
2.0 Days
Interval 1.0 to 4.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.5 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
3.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 4.0
|
2.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 6.0
|
1.5 Days
Interval 1.0 to 2.0
|
|
Duration of Solicited Local AEs
Ecchymosis (N=3;1;5;1;2;2;4;2;3;0)
|
5.0 Days
Interval 1.0 to 7.0
|
6.0 Days
Interval 6.0 to 6.0
|
6.0 Days
Interval 3.0 to 7.0
|
2.0 Days
Interval 2.0 to 2.0
|
2.5 Days
Interval 1.0 to 4.0
|
3.0 Days
Interval 1.0 to 5.0
|
3.0 Days
Interval 1.0 to 5.0
|
3.0 Days
Interval 2.0 to 4.0
|
5.0 Days
Interval 4.0 to 7.0
|
NA Days
None of the subjects in this group reported any ecchymosis.
|
|
Duration of Solicited Local AEs
Pain (N=68;82;111;84;91;119;93;106;32;93)
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
|
Duration of Solicited Local AEs
Redness (N=14;16;35;11;33;36;18;34;5;2)
|
1.5 Days
Interval 1.0 to 5.0
|
2.0 Days
Interval 1.0 to 6.0
|
3.0 Days
Interval 1.0 to 7.0
|
3.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
3.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 5.0
|
3.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 1.0
|
SECONDARY outcome
Timeframe: During a 7-day follow-up period (Day 0-6) after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature \>40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=201 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=201 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any myalgia
|
20 Subjects
|
35 Subjects
|
57 Subjects
|
30 Subjects
|
47 Subjects
|
66 Subjects
|
46 Subjects
|
56 Subjects
|
19 Subjects
|
40 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 headache
|
2 Subjects
|
1 Subjects
|
2 Subjects
|
0 Subjects
|
0 Subjects
|
4 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related headache
|
14 Subjects
|
23 Subjects
|
28 Subjects
|
18 Subjects
|
24 Subjects
|
27 Subjects
|
15 Subjects
|
27 Subjects
|
20 Subjects
|
30 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 myalgia
|
1 Subjects
|
1 Subjects
|
2 Subjects
|
1 Subjects
|
1 Subjects
|
3 Subjects
|
0 Subjects
|
2 Subjects
|
0 Subjects
|
1 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related myalgia
|
13 Subjects
|
29 Subjects
|
46 Subjects
|
24 Subjects
|
36 Subjects
|
46 Subjects
|
34 Subjects
|
44 Subjects
|
15 Subjects
|
33 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any nausea
|
10 Subjects
|
12 Subjects
|
19 Subjects
|
10 Subjects
|
13 Subjects
|
18 Subjects
|
8 Subjects
|
14 Subjects
|
6 Subjects
|
13 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 nausea
|
0 Subjects
|
2 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related nausea
|
6 Subjects
|
9 Subjects
|
10 Subjects
|
5 Subjects
|
8 Subjects
|
9 Subjects
|
4 Subjects
|
10 Subjects
|
4 Subjects
|
11 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any shivering
|
13 Subjects
|
18 Subjects
|
37 Subjects
|
26 Subjects
|
18 Subjects
|
43 Subjects
|
17 Subjects
|
31 Subjects
|
8 Subjects
|
21 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 shivering
|
1 Subjects
|
3 Subjects
|
2 Subjects
|
0 Subjects
|
0 Subjects
|
4 Subjects
|
0 Subjects
|
2 Subjects
|
0 Subjects
|
1 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related shivering
|
9 Subjects
|
14 Subjects
|
26 Subjects
|
21 Subjects
|
7 Subjects
|
27 Subjects
|
12 Subjects
|
21 Subjects
|
6 Subjects
|
16 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any fever
|
1 Subjects
|
1 Subjects
|
3 Subjects
|
2 Subjects
|
2 Subjects
|
6 Subjects
|
3 Subjects
|
6 Subjects
|
0 Subjects
|
1 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 fever
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related fever
|
1 Subjects
|
1 Subjects
|
3 Subjects
|
2 Subjects
|
1 Subjects
|
5 Subjects
|
3 Subjects
|
4 Subjects
|
0 Subjects
|
1 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any arthralgia
|
15 Subjects
|
23 Subjects
|
36 Subjects
|
16 Subjects
|
21 Subjects
|
45 Subjects
|
28 Subjects
|
35 Subjects
|
16 Subjects
|
12 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 arthralgia
|
3 Subjects
|
1 Subjects
|
2 Subjects
|
1 Subjects
|
0 Subjects
|
2 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related arthralgia
|
11 Subjects
|
15 Subjects
|
30 Subjects
|
10 Subjects
|
16 Subjects
|
28 Subjects
|
20 Subjects
|
25 Subjects
|
9 Subjects
|
9 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any fatigue
|
34 Subjects
|
35 Subjects
|
54 Subjects
|
35 Subjects
|
46 Subjects
|
55 Subjects
|
38 Subjects
|
63 Subjects
|
24 Subjects
|
41 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Grade 3 fatigue
|
0 Subjects
|
1 Subjects
|
3 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
2 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Related fatigue
|
21 Subjects
|
24 Subjects
|
39 Subjects
|
20 Subjects
|
35 Subjects
|
38 Subjects
|
25 Subjects
|
35 Subjects
|
16 Subjects
|
30 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any headache
|
22 Subjects
|
38 Subjects
|
47 Subjects
|
35 Subjects
|
39 Subjects
|
55 Subjects
|
36 Subjects
|
48 Subjects
|
23 Subjects
|
45 Subjects
|
SECONDARY outcome
Timeframe: During a 7-day follow-up period (Day 0-6) after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.
Duration was defined as number of days with any grade of general symptoms.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=34 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=38 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=57 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=35 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=47 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=66 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=46 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=63 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=24 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=45 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Solicited General AEs
Arthralgia (N=15;23;36;16;21;45;28;35;16;12)
|
3.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
3.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
|
Duration of Solicited General AEs
Fatigue (N=34;35;54;35;46;55;38;63;24;41)
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
|
Duration of Solicited General AEs
Headache (N=22;38;47;35;39;55;36;48;23;45)
|
1.5 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 5.0
|
1.5 Days
Interval 1.0 to 6.0
|
1.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
|
Duration of Solicited General AEs
Myalgia (N=20;35;57;30;47;66;46;56;19;40)
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 6.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
2.0 Days
Interval 1.0 to 7.0
|
|
Duration of Solicited General AEs
Nausea (N=10;12;19;10;13;18;8;14;6;13)
|
1.5 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 3.0
|
1.0 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 5.0
|
1.5 Days
Interval 1.0 to 5.0
|
1.0 Days
Interval 1.0 to 5.0
|
1.0 Days
Interval 1.0 to 7.0
|
1.5 Days
Interval 1.0 to 3.0
|
1.0 Days
Interval 1.0 to 6.0
|
|
Duration of Solicited General AEs
Shivering (N=13;18;37;26;18;43;17;31;8;21)
|
1.0 Days
Interval 1.0 to 3.0
|
1.0 Days
Interval 1.0 to 5.0
|
1.0 Days
Interval 1.0 to 6.0
|
1.0 Days
Interval 1.0 to 6.0
|
1.0 Days
Interval 1.0 to 5.0
|
1.0 Days
Interval 1.0 to 5.0
|
1.0 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 7.0
|
2.5 Days
Interval 1.0 to 7.0
|
1.0 Days
Interval 1.0 to 6.0
|
|
Duration of Solicited General AEs
Fever (N=4;3;9;4;3;14;6;12;0;1)
|
1.0 Days
Interval 1.0 to 1.0
|
3.0 Days
Interval 3.0 to 3.0
|
1.5 Days
Interval 1.0 to 2.0
|
1.5 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 1.0
|
1.0 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
NA Days
None of the subjects in this group reported any fever.
|
1.0 Days
Interval 1.0 to 1.0
|
SECONDARY outcome
Timeframe: During a 21-day follow-up period (Day 0-20) after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Any AE(s)
|
41 Subjects
|
32 Subjects
|
51 Subjects
|
39 Subjects
|
34 Subjects
|
42 Subjects
|
34 Subjects
|
43 Subjects
|
27 Subjects
|
44 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Grade 3 AE(s)
|
1 Subjects
|
3 Subjects
|
8 Subjects
|
3 Subjects
|
0 Subjects
|
6 Subjects
|
1 Subjects
|
6 Subjects
|
1 Subjects
|
3 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Related AE(s)
|
5 Subjects
|
7 Subjects
|
15 Subjects
|
6 Subjects
|
13 Subjects
|
13 Subjects
|
8 Subjects
|
18 Subjects
|
6 Subjects
|
13 Subjects
|
SECONDARY outcome
Timeframe: Between Day 0 and Day 20 after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20
Any AE(S)
|
15 Subjects
|
10 Subjects
|
19 Subjects
|
15 Subjects
|
16 Subjects
|
14 Subjects
|
11 Subjects
|
13 Subjects
|
10 Subjects
|
13 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20
Grade 3 AE(s)
|
0 Subjects
|
2 Subjects
|
4 Subjects
|
3 Subjects
|
0 Subjects
|
4 Subjects
|
1 Subjects
|
4 Subjects
|
1 Subjects
|
1 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20
Related AE(s)
|
0 Subjects
|
0 Subjects
|
4 Subjects
|
0 Subjects
|
1 Subjects
|
2 Subjects
|
0 Subjects
|
2 Subjects
|
1 Subjects
|
2 Subjects
|
SECONDARY outcome
Timeframe: Between Day 21 and Day 179 after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179
Any AE (s)
|
78 Subjects
|
60 Subjects
|
79 Subjects
|
71 Subjects
|
65 Subjects
|
67 Subjects
|
67 Subjects
|
69 Subjects
|
69 Subjects
|
62 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179
Grade 3 AE(s)
|
18 Subjects
|
11 Subjects
|
13 Subjects
|
13 Subjects
|
10 Subjects
|
12 Subjects
|
17 Subjects
|
15 Subjects
|
17 Subjects
|
10 Subjects
|
|
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179
Related AE(s)
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
SECONDARY outcome
Timeframe: Between Day 0 and Day 20 after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20
Any SAE(s)
|
0 Subjects
|
3 Subjects
|
2 Subjects
|
2 Subjects
|
2 Subjects
|
4 Subjects
|
2 Subjects
|
4 Subjects
|
0 Subjects
|
0 Subjects
|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20
Related SAE(s)
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
0 Subjects
|
SECONDARY outcome
Timeframe: Between Day 21 and Day 179 after vaccinationPopulation: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Outcome measures
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 Participants
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 Participants
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 Participants
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 Participants
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 Participants
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 Participants
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179
Any SAE(s)
|
18 Subjects
|
9 Subjects
|
5 Subjects
|
8 Subjects
|
9 Subjects
|
10 Subjects
|
16 Subjects
|
19 Subjects
|
15 Subjects
|
3 Subjects
|
|
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179
Related SAE(s)
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
0 Subjects
|
1 Subjects
|
0 Subjects
|
Adverse Events
Influenza Vaccine GSK576389A Formulation 1 Group
Serious events: 18 serious events
Other events: 107 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 2 Group
Serious events: 9 serious events
Other events: 129 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 3 Group
Serious events: 5 serious events
Other events: 150 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 4 Group
Serious events: 8 serious events
Other events: 121 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 5 Group
Serious events: 9 serious events
Other events: 138 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 6 Group
Serious events: 10 serious events
Other events: 158 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 7 Group
Serious events: 16 serious events
Other events: 134 other events
Deaths: 0 deaths
Influenza Vaccine GSK576389A Formulation 8 Group
Serious events: 19 serious events
Other events: 155 other events
Deaths: 0 deaths
Fluarix Elderly Group
Serious events: 15 serious events
Other events: 74 other events
Deaths: 0 deaths
Fluarix Young Group
Serious events: 3 serious events
Other events: 133 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 participants at risk
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 participants at risk
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 participants at risk
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 participants at risk
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 participants at risk
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 participants at risk
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 participants at risk
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Hypertensive cardiomyopathy
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Chest pain
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
1.0%
2/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Endocrine disorders
Goitre
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multiple myeloma
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Post procedural infection
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Skin injury
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.99%
2/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
1.5%
3/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Arrhythmia
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Angina unstable
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Psychiatric disorders
Depression
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Haematoma
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Left ventricular failure
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Pneumonia
|
0.98%
2/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Syncope
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign salivary gland neoplasm
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Bifascicular block
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Bleeding varicose vein
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Coronary artery disease
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Cystitis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Diverticulitis
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Gangrene
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Gastroenteritis norovirus
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Eye disorders
Glaucoma
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Headache
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Herpes Zoster
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Hypertension
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Hypertensive crisis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Hypovolaemic shock
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Gastrointestinal disorders
Ileus
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.49%
1/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.49%
1/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Neuritis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.49%
1/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Reversible ischaemic neurological deficit
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Cardiac disorders
Sick sinus syndrome
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Syncope vasovagal
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Eye disorders
Ulcerative keratitis
|
0.49%
1/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Vascular disorders
Varicose vein
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Ear and labyrinth disorders
Vestibular disorder
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.50%
1/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Ear and labyrinth disorders
Vestibular neuronitis
|
0.00%
0/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.51%
1/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
0.00%
0/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
Other adverse events
| Measure |
Influenza Vaccine GSK576389A Formulation 1 Group
n=204 participants at risk
Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 2 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 3 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 4 Group
n=202 participants at risk
Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 5 Group
n=199 participants at risk
Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 6 Group
n=198 participants at risk
Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 7 Group
n=198 participants at risk
Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
|
Influenza Vaccine GSK576389A Formulation 8 Group
n=199 participants at risk
Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
|
Fluarix Elderly Group
n=200 participants at risk
Subjects aged ≥65 years received one dose of Fluarix vaccine.
|
Fluarix Young Group
n=203 participants at risk
Subjects aged 18-40 years received one dose of Fluarix vaccine.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Pain
|
33.8%
68/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
40.8%
82/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
55.2%
111/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
41.8%
84/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
46.0%
91/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
60.4%
119/197 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
47.0%
93/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
53.5%
106/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
16.0%
32/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
46.3%
93/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Redness
|
7.5%
15/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
8.0%
16/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
18.4%
37/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.0%
12/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
16.7%
33/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
18.3%
36/197 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.1%
18/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.2%
34/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
2.5%
5/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
1.00%
2/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Swelling
|
6.5%
13/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.0%
12/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
12.4%
25/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.5%
13/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.1%
18/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
11.7%
23/197 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
5.6%
11/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
12.6%
25/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
2.5%
5/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
1.00%
2/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Arthralgia
|
7.5%
15/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
11.4%
23/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.9%
36/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
8.0%
16/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
10.6%
21/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
22.7%
45/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
14.1%
28/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.7%
35/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
8.0%
16/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.0%
12/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Fatigue
|
16.9%
34/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.4%
35/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
26.9%
54/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.4%
35/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
23.2%
46/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
27.8%
55/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
19.2%
38/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
31.8%
63/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
12.0%
24/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
20.4%
41/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Headache
|
10.9%
22/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
18.9%
38/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
23.4%
47/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.4%
35/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
19.7%
39/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
27.8%
55/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
18.2%
36/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
24.2%
48/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
11.5%
23/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
22.4%
45/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Myalgia
|
10.0%
20/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
17.4%
35/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
28.4%
57/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
14.9%
30/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
23.7%
47/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
33.3%
66/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
23.2%
46/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
28.3%
56/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.5%
19/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
19.9%
40/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Nausea
|
5.0%
10/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.0%
12/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.5%
19/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
5.0%
10/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.6%
13/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.1%
18/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
4.0%
8/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
7.1%
14/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
3.0%
6/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
6.5%
13/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
General disorders
Shivering
|
6.5%
13/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.0%
18/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
18.4%
37/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
12.9%
26/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
9.1%
18/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
21.7%
43/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
8.6%
17/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
15.7%
31/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
4.0%
8/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
10.4%
21/201 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
|
Infections and infestations
Nasopharyngitis
|
4.4%
9/204 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
2.0%
4/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
3.5%
7/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
2.5%
5/202 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
3.5%
7/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
4.0%
8/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
3.0%
6/198 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
3.5%
7/199 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
1.0%
2/200 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
5.4%
11/203 • Serious adverse events were assessed from day 0 to day 20 and day 21 to day 179. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.
For the systematically assessed other (non-serious) adverse events,the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.
|
Additional Information
GSK Response Center
GlaxoSmithKline
Phone: 866-435-7343
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER